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Abbreviation
Ab  Antibody
Ag   Antigen
APC   Antigen presenting cells
AU  Analytical ultracentrifugation
CDR  Complementary determining region
CHES 2-(N-cyclohexylamino) ethanesulfonic acid
Da  Dalton
DC  Dendritic cell
DTT  Dithiothreitol
EDTA Ethylenediaminetetraacetic acid
Fab  Fragment antigen binding
Fc  Fragment crystallizable
FWR  Frame work region
GPI  Glycosyl phosphatidylinositol
HA  Hyaluronic acid or hyaluronan
Hya  Hyaluronidase
Hyal   Hyaluronidase (mammals)
His-tag Hexahistidine tag
IgG  Immunoglobulin G
IL  Interleukin
kDa  Kilo dalton
LS-MS  Liquid chromatography-Mass spectrometry
mAb  Monoclonal antibody
MALDI-TOF  Matrix assisted laser desorption ionization-Time of flight
min  Minute
MW  Molecular weight
OD  Optical density
PEG  Polyethylene glycol
PDB  Protein data bank
PH2060 60-kDa PH-20 protein purified from commercial bovine  testicular ex- 
 tract (Sigma)
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PH2069 69-kDa PH-20 protein purified from commercial bovine testicular  ex- 
 tract (Sigma) 
PH2080 80-kDa PH-20 protein purified from bovine testes 
PI-PLC Phosphatidylinositol-specific phospholipase C
PMSF Phenylmethylsulphonyl fluoride
Rfactor  Crystallographic residual for working set of reflections
Rfree  Crystallographic residual for test set of reflections 
RT  Room temperature 
rms  Root-mean-squared
rpm  Rotation per minute
SDS-PAGE Sodium dodecylsulphate-polyacrylamide gel eclectrophoresis
SPAM1 Sperm adhesion molecule1
TABS N-tris[Hydroxymethyl]methyl-4-aminobutanesulfonic acid
TCR  T-cell receptor
Th2  T helper cell 2
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1.0  Hyaluronidases: background and significance
1.0 Hyaluronidases: background and significance
The hyaluronidases are the enzymes, which hydrolyze β-1, 4 glycosidic linkage of hya-
luronan (Hyaluroronic acid, HA) [1], a linear, non-sulfated polysaccharide composed of repeat-
ing disaccharide units [D-glucuronic acid (1-β-3) N-acetyl-D-glucosamine (1-β-4)]n (Figure 1) 
[1, 2]. HA is ubiquitously distributed in the extracellular matrix of vertebrates, particularly 
abundant in the soft  connective tissues such as cartilage, synovial fluid, umbilical cord etc. The 
viscoelastic properties of HA, determined by its concentration and molecular weight, enable 
HA to act  as stabilizer, lubricant, and shock absorbent. The level of HA is markedly elevated in 
many biological processes in which high turnover of HA is required such as embryogenesis, 
cell migration, wound healing, malignant transformation, and tissue turnover. [3].   
Figure 1. Structure of hyaluronan. The polymer is built of alternating units of glucuronic acid 
(GlcUA) and N-acetylglucosamine (GlcNac). All the glycosidic linkages are β type, 1-3 glyco-
sidic bonds between GlcUA and GlcNac, and 1-4 bonds between GlcNac and GlcUA. The 
vertebrate hyaluronidase cleaves the β  1-4 glycosidic bond between GlcUA-GlcNac as 
shown.
Hyaluronidases are widely distributed in nature, being found in mammals, insects, 
leeches and bacteria [1, 2]. Hyaluronidase (Hya) activity was first  identified as a ‘spreading 
factor’ based on the spreading properties exhibited by the extracts from mammalian testes. Hya 
from different  sources are classified under three distinct classes based on substrate specificity 
and biochemical analyses of the reaction products as outlined in Karl Meyer 1971 [1]. 
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‣ Group 1 is represented by the mammalian hyaluronidases (E.C. 3.2.1.35) and the enzymes 
from venom of insects, snakes, scorpions which hydrolyze β-1, 4 glycosidic bond between 
GlcNac and GlcUA, generating tetra- and hexasaccharides as the predominant end products. 
They also digest chondroitin sulfate and to small extent dermatan sulfate. Bee venom hyalu-
ronidase and PH-20 protein from mammalian testis are best characterized enzymes. 
‣ Group 2 is represented by leeches enzymes (E.C. 3.2.1.36) which act as endo-β-
glucuronidases. These enzymes generate tetra- and hexasaccharide end products.
‣ Group 3 comprises bacterial HA-lyases (E.C. 4.2.99.1) that  act  as endo-N-acetyl-
hexosaminidases by β-elimination, yielding predominantly disaccharides as end products. 
Based on the sequence homology, hyaluronidases from insect  (honeybees and vespids) 
venom and mammalian hyaluronidases (EC 3.2.1.35) found in tissues (testis and plasma), 
snakes and scorpion enzymes have been classified into the glycosidase family 56 [4, 5]. Hya 
from honey bee venom shares greater than 50% sequence identity with other hymenopterans 
Hya [6, 7] and 30% sequence identity with the sperm PH-20, involved in fertilization, and the 
human lysosomal enzymes Hyal-1 and Hyal-2 which regulate HA turnover [8, 9]. The crystal 
structure of bee venom hyaluronidase, the first  representative structure of glycosidase family 
56, has been determined at  1.6 Å resolution. The overall fold resembling closely a classical (α/
β)8 TIM barrel with the exception that  seven β-strands form the barrel [9]. The structure of Hya 
in complex with HA-tetramer (2.65 Å) enabled the elucidation of an acid-base catalytic mecha-
nism in which Glu113 acts as the proton donor whereas the N-acetyl group of the substrate is 
the nucleophile. This unusual substrate-assisted acid-base catalytic mechanism is most  proba-
bly also used by homologous mammalian enzymes since the active site residues and the resi-
dues in the substrate binding cleft  are highly conserved. In addition, four cysteine residues 
forming two disulfide bridges are highly conserved (Figure 2). In comparison to bee venom 
hyaluronidase (350 residues), vertebrate hyaluronidases have an additional C-terminal domain 
EGF-like domain in Hyal-1 and a putative cell adhesion domain in PH-20. In addition, C-
terminus of PH-20 has a transmembrane glycosyl phosphatidylinositol (GPI) lipid anchor [10, 
11] (Figure 3). 
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Figure 2. Multiple sequence alignment of hyaluronidases. The proteins listed from top  to bot-
tom: bee venom hyaluronidase (residues 1-350, NCBI accession number Q08169), wasp 
hyaluronidase (1-337, Q9U6V9), bovine PH-20 protein (1-353, Q7YS45), human lysosomal 
hyaluronidase Hyal-1 (1-349, Q12794) and human Hyal-2 (1-355, Q12891). Fully conserved 
residues shown in red box with white character and partially conserved residues shown in red 
character. Secondary structure elements are shown in top of the sequence. Blue arrowheads 
denote the active site residues Asp111 and Glu113. The four cysteine residues forming two 
disulfide bridges, Cys22-Cys313 (marked as 1 in green color) and Cys189-Cys201 (marked 
as 2 in green colour). Two N-glycosylation sites of bee venom hyaluronidase are indicated by 
(✭) on the bottom of the sequence alignment. 
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Figure 3. Diagram represents the putative domains in bee venom hyaluronidase, Hyal-1 
(plasma hyaluronidase) and PH-20/sperm adhesion molecule 1(SPAM1). The N-terminal 
region shows strongest homology between the three enzymes (indicated in blue). The C-
terminal domain of the mammalian enzymes shows minimal homology and is absent in the 
bee venom enzyme. PH-20 has zona pellucida binding domain in the C-terminal region. 
Similarly Hyal1 has EGF-like domain in the C-terminal region  which has sequence homol-
ogy to serrate protein in the fruit fly, Drosophila melanogaster, and to Xotch protein in the 
frog, Xenopus laevis. Relative polypeptide lengths are drawn to scale. The picture adapted 
from  Glycoforum’s ‘Hyaluronan Today’, of Seikagaku Corp 
(www.glycoforum.gr.jp/today.html).
Bee venom hyaluronidase: It  is one of the major allergens present  in bee venom which spe-
cifically degrades HA in the extracellular matrix of skin thereby facilitating penetration of 
venom constituents into the body [12]. Native hyaluronidase, isolated from honeybee venom, is 
a single chain secreted protein composed of 350 amino acids, which is derived from a precursor 
composed of a signal peptide and a short prosegment. Recombinant His-tagged Hya expressed 
in eukaryotic (Baculovirus) expression system, has enzymatic activity and IgE-binding capacity 
similar to native Hya [13]. Hya contains four potential N-glycosylation motifs (Asn-X-Thr, 
where X is any amino acid). The crystal structure of the recombinant (Baculovirus) bee venom 
hyaluronidase shows that  the Asn residues at 83 and 231 have weak density extending from 
these residues, which is indicative of glycosylation. In contrast, Asn191 is buried in the protein 
interior so that  it  can be ruled out as glycosylation site and Asn4 in the N-terminus is not de-
fined by electron density. Hya contains two disulfide bridges: Cys189-Cys201 which stabilizes 
the base of a long loop at  the C-terminal end, whereas the Cys22-Cys313 bridge joins the sec-
ondary structure elements, a 310 helix near the N-terminus and α-helix near the C-terminus. 
The prominent feature of Hya structure is the large gap between stands 1 and 2 (7-8Å) and a 
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Figure 4. Ribbon representation of the bee venom hyaluronidase. The barrel formed by 
β  strands 1-7 (green arrows), α helices marked A-J (red spirals) on the outside of the 
barrel and 310  helices in orange. The substrate binding groove is located at the C-
terminal end of the  β  barrel and the active site residues Asp111 and Glu113 are shown 
as stick models.
long groove formed by the loops at the C-terminal end of β-barrel, suited for substrate binding. 
Another unusual feature is the presence of two α-helices (helix C and D) resembling a ‘handle’ 
like structure which extend away from globular domain (Figure 4) [9].
Mammalian hyaluronidases: Mammalian hyaluronidases are presumably responsible for hya-
luronan (HA) turnover in diverse tissue but the details of HA catabolism remain obscure. 
Mammalian genome consists of six hyaluronidase genes, clustered into two groups and shares 
40% sequence identity to each other. In the human, three genes (HYAL1, HYAL2 and HYAL3) 
are found tightly clustered on chromosome 3p21.3 and likewise, another three genes HYAL4, 
HYALP1 (a pseudogene), and PH-20/SPAM1 are clustered on chromosome 7q31.3 (Figure 5) 
[11]. The extensive homology between the different hyaluronidase genes suggests ancient gene 
duplication. Correspondingly, mouse genome also contains six hyaluronidase genes, except 
HYALP1 ortholog does not contain any mutation, and may encode for an active enzyme.
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Figure 5. Depicts the chromosomal orientation of the six hyaluronidase genes at their 
two respective chromosomal sites, and tabulation of their gene products. The relative 
gene order has been established for the chromosome 7, but their orientation in rela-
tion to the centromere and telomere has not yet been  determined. This figure is not 
drawn to scale. Picture was adapted from Glycoforum’s ‘Hyaluronan Today’, of 
Seikagaku Corp (www.glycoforum.gr.jp/today.html).
PH-20, Hyal-1 and Hyal-2 are well characterized mammalian hyaluronidase. PH-20 is 
expressed only in the testis and plays important  role in mammalian fertilization (more details 
under PH-20/Sperm adhesion molecule 1). Hyal-1 and Hyal-2 are expressed in the somatic tis-
sues such as liver, kidney, spleen etc., and the expression of these enzymes are extremely low 
and difficult to purify. Recent development in Hya detection procedure (substrate gel assay) 
[14] has facilitated the purification of 57 kDa molecular weight  Hyal-1 to homogeneity from 
human plasma [15]. In contrast to plasma, urine contains two hyaluronidases with molecular 
weight  of 57 kDa and 45 kDa. Microsequencing confirmed that both urinary isozymes have N-
terminal identical to plasma hyaluronidase. Lower molecular weight  isozyme contains a second 
N-terminal sequence, which was derived from the C-terminal end of the protein. This suggests 
that 45 kDa isozyme, resulting from endoproteolytic cleavage of the 57 kDa isoform, consists 
of two polypeptides linked by disulfide bond [16]. In vertebrates, the turnover of HA is con-
trolled by hyaluronidase, which is an endoglycosidase that acts jointly with two lysosomal exo-
glycosidases, β-glucuronidase and β-N-acetyl glucosaminidase. 
Hyal-3 is widely expressed enzyme but no activity was identified by present hyaluroni-
dase assay [17]. In contrast to other hyaluronidases, Hyal-4 appears to have specificity for 
chondroitin and chondroitin sulfate, with no activity against hyaluronan [4]. In addition, Hyal-
2, Hyal-4 and PH-20 are GPI-anchored on the plasma membrane [11]. 
Biological and medical significance of hyaluronidases:
★ The PH-20 protein plays a major role in mammalian fertilization. The male and female 
guinea pig immunized with PH-20 showed 100% contraception and the effect  was long 
lasting and reversible [18]. This suggest PH-20 can be effectively used as a contraceptive 
vaccine.
★ The level of HA surrounding tumor cells often correlates with tumor aggressiveness and 
overproduction of HA enhance anchorage-independent cell growth [19-21]. Loss of hyalu-
ronidase activity, permitting accumulation of HA, which might  be one of the several steps 
required by cells during carcinogenesis. In addition, hyaluronidase expression was seen in 
various metastatic cell lines, which suggest  tumor cells use hyaluronidase as "molecular 
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destroyer" to depolymerize hyaluronic acid in surrounding tissues and facilitate tumor in-
vasion. Hyaluronidase on tumor cells may provide a target for anti-neoplastic drugs [22].
★ Testicular enzyme is used as a ‘spreading factor’, to improve better penetration of chemo-
therapeutic drug into tumors. Drawback of this approach is hyaluronidase developed symp-
toms of immediate type 1 allergic reaction [23]. 
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The thesis is divided in two parts:
In the first  part, I discuss the crystal structure determination of bee venom hyaluronidase in 
complex with a Fab fragment of an anti-Hya monoclonal IgG antibody (clone 21E11) which is 
able to compete with human IgE, from the bee venom allergic patient  serum pool into Hya 
binding. Hya is one of the major allergen present  in honeybee venom that may induce life 
threatening allergic reaction in human. Since the allergen-antibody interactions are crucial for 
triggering of allergic responses, the structures of the antigen/antibody complexes are essential 
for the identification of Hya epitopes recognized by IgE antibodies. The knowledge of B cell 
epitope may facilitate the design of new and safer vaccines for allergen immunotherapy in the 
form of mutated allergens with abolished or reduced IgE binding potency (hypoallergen).
In the second part, I discuss the PH-20 protein, a mammalian hyaluronidase which plays impor-
tant role in fertilization. Though mammalian hyaluronidases play important role in many bio-
logical processes, the study of these enzymes is greatly neglected. In the present  study, we were 
able to purify PH-20 proteins from commercially available testicular extract (Sigma) and from 
the homogenized bovine testes to highest purity. The aggregation of purified PH-20 was suc-
cessfully eliminated by the addition of zwitterionic compound, NDSB (non detergent sulfobe-
taine). Attempt to crystallize the PH-20 protein were not  successful but  crystallization in the 
presence of NDSB still remains to be tested.
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 2.0  Identification of a B-cell epitope of hyaluronidase, a major 
bee venom allergen, from its crystal structure in complex with a 
specific Fab (S.Padavattan et al., JMB, v. 368, p. 742-52)
                                                                                               Hya/Fab complex structure 
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0022-2836/$ - see front matter © 2007 EThe major allergens of honeybee venom, hyaluronidase (Hyal) and
phospholipase A2, can induce life-threatening IgE-mediated allergic
reactions in humans. Although conventional immunotherapy is effective,
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Venoms of bees, wasps and fire ants can cause
severe IgE-mediated allergic reactions (type I
hypersensitivity) including anaphylaxis.1–3 It has
been estimated that up to 3% of the general
population have a history of systemic anaphylactic
reactions to insect stings.4 Venoms from bee and
wasp are different, each containing distinct major
allergens: phospholipase A2 and melittin occur
only in bee venom, and antigen 5 only in wasp
venom, but both venoms contain hyaluronidases
(Hyal).3 Clinical studies demonstrated that Hyal
and phospholipase A2 are the two major allergens
present in bee venom: 71% of patients had specific
serum IgE against recombinant Hyal and 78%
against recombinant phospholipase A2.5 Suscep-
tible individuals respond to bee venom exposure
by producing IgE antibodies which bind to the
high affinity Fc receptors on basophils in circula-
tion or mast cells in tissues. Following re-
exposure, multivalent allergens cross-link Fc-recep-
tor-bound IgE antibodies on the surface of mast
cells. This leads to a series of signaling events,
which result in mast cell degranulation and the
release of histamine, leukotriene and other med-
iators which are responsible for a variety of
allergic symptoms.
Bee venom Hyal is a hydrolytic enzyme that
specifically cleaves the hyaluronic acid, a large,
linear polymer (hyaluronan) consisting of simple
repeats of disaccharide composed of the β-1,4 linked
D-glucuronic acid and N-acetyl-glucosamine. Hya-
luronan and chondroitin sulfates are the most
abundant glycosaminoglycan of vertebrate extra-
cellular matrix, and the relative abundance of these
glycoproteins varies with the origin of the connec-
tive tissue. Cleavage of hyaluronan by Hyal facil-
itates the penetration of venom constituents into the
body.6 Hyaluronan is found in almost all tissues and
body fluids and is particularly abundant in the
intercellular matrix of skin and the connective
tissues of cartilage, synovial fluid and the vitreous
humor of the eye. Under physiological conditions,
hyaluronan is a large (105 to 107 kDa), charged and
extended polysaccharide which is exceptionally
hydrophilic. The ability to bind large amounts of
water confers special viscoelastic properties to
hyaluronan solutions which are the basis of its
structural role as a stabilizer, joint lubricant and
shock absorber.7,8 Hyaluronan exists in a number of
physiological states, associated with themselves,
with the extracellular matrix, with the cell surface
receptors CD44 and RHAMM9 present on the
hyaluronan-binding proteins (hyaladherins)10–12
forming massive multimolecular aggregates with
proteoglycans, such as aggrecan.
Bee venom Hyal is composed of 350 amino acids
and has four potentialN-glycosylation sites and two
disulfide bridges. In fact, only two of the four
postulated sites are N-glycosylated, Asn115 and
Asn263.13–15 Recombinant Hyal has been expressed
in prokaryotic (Escherichia coli) and eukaryotic(Baculovirus) hosts. Only the Baculovirus-expressed
enzyme has enzymatic activity and IgE-binding
capacity similar to native Hyal.16 The crystal
structure of the recombinant (Baculovirus) bee
venom Hyal13 is the first structural representative
of the Hyals belonging to the glycosidase family
56.17,18 The overall fold of Hyal resembles a classical
(β/α)8 barrel except that the barrel is formed by
seven β strands and is open between β strands 1 and
2. The structure of Hyal in complex with hyaluronic
acid-tetrameres enabled to propose an acid–base
catalytic mechanism in which Glu113 acts as the
proton donor and the N-acetyl group of the
substrate as the nucleophile.13,19 Recently, the
structure of homologous wasp Hyal has been solved
showing a fold identical with that of bee venom
Hyal.20
Specific immunotherapy (SIT) is the only causal
treatment for type I allergies; however, a drawback
is the risk of IgE-mediated anaphylactic side effects,
which occur in 20%–40% of patients21 subjected to
SIT based on natural extracts. There is evidence that
successful immunotherapy operates on the level of T
helper cells, leading to marked changes in cytokine
secretion patterns: TH2 cells secreting IL-4, IL-5 and
IL-13 diminish strongly and are replaced by IL-10
secreting CD4+CD25+ regulatory cells (TReg).
22,23
Furthermore, it has been shown that immunother-
apy induces allergen-specific IgG antibodies which
inhibit the binding of allergic patients IgE to the
allergen.24,25 One way to lower the risk of anaphy-
laxis during SIT is to use allergens modified in a way
which abolishes or reduces its IgE-binding potency
(hypoallergen) but retains the allergen T-cell epi-
topes (linear epitopes) that will induce T-cell
tolerance.23 Other possibilities are to prepare geneti-
cally modified allergens or allergen-derived pep-
tides with reduced allergenic activity which induce
protective allergen-specific IgG antibodies compet-
ing with IgE.26
Since allergen–antibody (Ab) interactions are
crucial for the triggering of allergic responses, a
promising approach to inhibit this process would
be to prevent allergen binding to IgE. Determining
the structure of antigen (Ag)/Ab complexes is one
way to identify the Hyal epitopes which are
recognized by IgE antibodies. The knowledge of
the B-cell epitope of the allergen is expected to
facilitate the design of a safer SIT in the form of
mutated allergens with reduced IgE-binding
potency which would be able to bypass the risk
of anaphylaxis.
In the present study, a monoclonal murine IgG1
antibody (mAb, clone 21E11) raised against purified
recombinant Hyal and able to inhibit IgE binding to
Hyal up to 60% in some patients, was chosen to map
the B-cell epitope. This is the second study of an
allergen–Ab complex, after the Bet v 1–Fab (frag-
ment of IgG which binds to antigen (Fab)) complex
structure, although many Ag–Fab complex struc-
tures have been reported.27–30 It is anticipated that
the knowledge of the Hyal epitope may be used to
genetically modify the allergenic protein in order to
Table 1. Reactivity of mouse mAbs specific for Api m 2
Absorbance
21E11
Absorbance
22H7
Absorbance
24F2
Peptide (R138–E152) 0.03 0.03 0.03
Api m 2 0.90 1.11 0.67
HSA 0.03 0.03 0.03
Absorbance values corresponding to the levels of mouse
monoclonal IgG1 antibodies (mAbs: 21E11, 22H7, 24F2) specific
for Api m 2 and the Api m 2-derived peptide are displayed.
Human serum albumin (HSA) was used as negative control.
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safer immunotherapy.Results
Inhibition of IgE binding to Hyal by anti-Hyal
monoclonal IgG1 Abs
Hyal (rApi m 2) is recognized by serum IgE from
bee venom allergic patients and also by three
different mouse monoclonal IgG1 antibodies (clones
21E11, 22H7 and 24F2). In contrast, the Hyal derived
15-mer peptide (Arg138–Glu152) containing nine
epitope residues elucidated from the Hyal/Fab
complex structure, is not recognized by the mAbs
(Table 1). Also sera of bee venom allergic patients do
not bind to the isolated peptide (data not shown).
The effect of the three mouse mAbs on binding of
serum IgE from 10 bee venom allergic patients was
tested by an ELISA-inhibition assay (Table 2). A
mean inhibition of IgEs binding to Hyal by each of
the three mAbs ranged between 18% and 20%.
However, this value was as high as 57% for certain
patients' sera.
Structure determination of the Hyal/Fab complex
The crystal structure of the complex formed
between Hyal and the Fab fragment of the mouse
mAb 21E11 has been determined at 2.6 Å resolutionTable 2. Inhibition of IgE binding of bee venom positive sera
Individual
Absorbance
mAb control
Absorbance
21E11
%
inhibitiona
Absorbance
22H7 in
I 2.57 1.98 23.02 2.28
II 1.47 1.15 21.77 0.99
III 1.39 1.67 – 1.43
IV 1.18 0.87 26.36 1.01
V 0.61 0.58 5.06 0.58
VI 0.54 0.23 56.83 0.25
VII 0.32 0.30 6.48 0.25
VIII 0.39 0.35 9.51 0.34
IX 0.32 0.31 2.79 0.28
X 0.22 0.15 32.72 0.16
Mean 18.45
a rApi m 2 bound to ELISA plate was pre-incubated with three
(mAbs:21E11, 22H7, 24F2), a mixture of all three mAbs and, for contro
plates were then incubated with sera of 10 bee venom allergic patien
inhibition of IgE binding is shown.by molecular replacement (MR) (Table 3). MR was
performed in three consecutive steps using the
structures of apo Hyal (1FCQ), Fab variable domain
(1A7Q) and constant domain (15C8) as the search
models. This yielded the orientation and location
of the three constituents in the asymmetric unit. The
final model comprises residues Glu10–Ser333 of
Hyal, Asp1–Ile205 of the light chain and Gln1–
Val180 of the heavy chain of Fab as well as 63 water
molecules. The Fab residues are numbered as de-
scribed by standard Kabat convention with light
and heavy chain identifiers L and H, respectively.31,32
In Hyal, the electron density is missing for 9 N-
terminal and 17 C-terminal residues (plus the His6
tail) and loop residues Asp66–Asn70. Likewise, in
Fab density is missing for residues L119–L131,
L150–L157, L168–L169, L187–L192 and L206 to the
C-terminal end of the light chain, and for residues
H122–H137, H157–H162 andH181 to the C-terminal
end of the heavy chain.Most of these residues belong
to the loops of the constant domain and are far away
from the Hyal/Fab interface. After conventional
refinement, the final model has an R-factor of 20.9%
(Rfree, 24.7%) at 2.6 Å resolution (Table 3). The
residues are well ordered and exhibit good stereo-
chemistry (Table 3). The electron density is of good
quality; an example of the final 2Fo–Fc map is shown
in Figure 1.
Overall fold of the Hyal/Fab complex
The structure of the Hyal/Fab complex is shown
as a ribbon presentation in Figure 2(a). The Hyal fold
is a (β/α)7 barrel open between strands 1 and 2 and
surrounded by 10 α helices.13 The overall Ag
conformation is not changed significantly upon
complex formation. Superposition of the apo Hyal
models 1FCQ (1.6 Å resolution) and 1FCU (2.1 Å
resolution)13 with Hyal of the Hyal/Fab complex
gives r.m.s.d. of 0.76 and 0.61 Å (for 312 and 319 Cα
atoms), respectively, which is comparable with the
differences observed between the two unliganded
Hyal models (r.m.s.d. of 0.68 Å for 314 Cα atoms). In
protein Ag/Ab complexes, conformational adjust-to purified recombinant Api m 2 by mAbs
%
hibition
Absorbance
24F2
%
inhibition
Absorbance
21E11/22H7/24F2
%
inhibition
11.14 1.97 23.26 2.20 14.14
32.56 1.00 31.95 0.98 32.76
– 1.21 12.83 1.17 15.28
14.54 1.23 – 0.94 20.41
4.73 0.59 4.08 0.43 29.20
54.79 0.27 49.82 0.22 60.15
21.61 0.27 17.91 0.21 36.42
13.88 0.34 13.11 0.27 31.36
11.80 0.28 13.98 0.25 23.91
26.73 0.16 28.57 0.16 26.73
19.18 19.55 29.04
individual Api m 2-specific mouse monoclonal IgG1 antibodies
l purposes, with a mouse mAb against Bet v 1 (mAb control). The
ts. Api m 2-specific IgE levels were measured. The percentage of
†http://bioinfo.ernet.in/cep.htm
Table 3. Crystallographic data for Hyal/Fab complex
Data collection
Space group C2
Unit cell dimensions
a, b, c (Å) 151.6, 70.1, 138.9
α, β, γ (°) 90.0, 123.7, 90.0
X-ray source SLS-PX
Detector type MAR CCD
Wavelength (Å) 0.978
Resolution range (Å) 63–2.6 (2.74–2.6)a
No. of total observation 101,732 (14,135)
No. of unique observation 32,047 (4437)
Completeness (%) 85.4 (81.8)
Multiplicity 3.2 (3.2)
I/σ(I) 13.9 (3.6)
Rsym
b (%) 8.4 (30)
Refinement
Rfactor/Rfree
c (%) 20.9/24.7
Protein atoms 11642
Water molecules 63
Average B-factor (Å2)
Hyal 37.5
Fab variable domain 38.0
Fab constant domain 38.2
Solvent 33.8
r.m.s.d. from ideal values
Bond lengths (Å) 0.009
Bond angles (°) 1.136
r.m.s. ΔB of bonded atoms (Å2)
Main chain 1.020
Side-chain 2.257
Ramachandran plot
Most favored region (%) 88.4
Additionally allowed region (%) 10.3
Generously allowed region (%) 0.5
Disallowed region (%) 0.7
a Number in parentheses are statistics for the data in the
highest resolution shell.
b Rsym=ΣΣ|I(h)i− 〈I(h)〉|/ΣΣ I(h)i, observed intensity in the
ith data set and 〈I(h)〉, mean intensity of reflection h over all
measurements of I(h).
c Rfactor is the conventional R-factor and Rfree is the R-factor
calculated with 5% of the data that were not used in refinement.
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acting residues upon complex formation is often
observed.29 In Hyal, the largest deviations in the Cα
position occur in loop residues His141–Asp145,
which are part of the epitope (r.m.s.d.=2.6 and
2.1 Å for 1FCQ and 1FCU, respectively), indicating
a considerable conformational change of the epi-
tope loop upon Fab binding (Figure 2(b)). However,
also the conformation of residues Thr193–Pro197
from the loop which is far from the Ab binding site
(r.m.s.d.=2.3 Å) is significantly changed. In the
absence of the structure of the free Ab, the extent of
possible conformational changes of the residues be-
longing to the variable domain cannot be evaluated.
The Hyal/Fab interface
The mAb 21E11 recognizes a continuous epitope
located at the tip of the helix C–turn–helix Dmotif of
Hyal, which resembles a handle that protrudes
away from the globular core of the molecule (Figure
2(a)). The total contact surface area of the complexinterface was estimated to be 1274 Å2 (probe radius
1.7 Å, program MS). The epitope is mostly contin-
uous and composed of eight consecutive residues
His141–Arg148 (HPFWDDQR) plus Arg138. Hyal
structure was submitted to CEP-server for the
prediction of conformational epitopes†.33 In addi-
tion to the predicted conformational epitopes, the
server predicted a sequential epitope at position
Arg138–Gln151. This prediction is in good agree-
ment with the results from our crystal structure,
which showed that 9 of 14 residues predicted by the
server are indeed involved in Fab binding. All nine
residues belong to the C- and N-terminal ends of
helices C and D and the joining turn (Figure 2(c)).
Epitope residues fit tightly into the deep pocket
formed by the side-chains from all six complemen-
tarity determining regions (CDRs) and the light
frame work region 2 (FWR L2) of the Fab (Figures
2(c) and 3). The interface is formed by 9 Hyal and 17
Fab residues. The total number of polar Hyal/Fab
interactions comprises 4 salt bridges and 9 hydrogen
bonds while 11 and 39 van der Waals contacts have
been found for the cut off values of 3.7 Å and 4.0 Å,
respectively (Table 4). Of the nine epitope residues in
contact with Fab, two are polar, four are charged
and three are hydrophobic. The polar and charged
residues are located predominantly at the periphery
of the Hyal binding surface, the two hydrophobic
residues (Pro142, Phe143) from the turn are buried
at the bottom of Hyal/Fab cavity formed by the
hydrophobic residues of Fab, whereas Trp144 is
only 79% buried (Figures 2(c) and 3). The size of the
Fab binding pocket is approximately 14 Å wide and
15 Å deep. The salt bridges are formed between
Asp145 and Arg148 from helix D of Hyal and Arg58
and Asp54 from CDR-H2 of Fab, respectively
(Figure 3).
Water molecules are often found in the interfaces
of Ag–Ab complexes34–36 where they are required to
improve the fit between the proteins and to
neutralize unpaired hydrogen-bonding groups. In
the Hyal/Fab complex, three water molecules (21O,
22O and 23O) are completely buried between the
two surfaces, filling the cavity and enhancing
surface complementarity (Table 5). Three additional
water molecules (5O, 20O and 45O) are present at
the periphery of the interface where they enable
Hyal–water–water–Fab hydrogen bonding interac-
tion. The shape correlation statistic for Hyal/Fab
complex is 0.73 which is slightly higher than the
observed mean shape correlation statistic value of
0.64–0.65 for Ag–Ab interface,37 indicating good
shape complementarity. Thus, the Hyal/Fab com-
plex structure also confirms the importance of
bound water molecules in mediating protein/
protein interactions.
The Ab combining site is a pronounced cavity
formed by the side-chains of the Fab residues
interacting with Hyal: six residues from the light
chain CDRs (L1, L2 and L3), nine residues from the
Figure 1. Close-up stereo view of the final SigmaA-weighted 2Fo–Fc electron density map60 contoured at 1.0σ. Shown
is part of the Hyal/Fab interface with Hyal and Fab heavy chain colored magenta and yellow, respectively. All pictures
were produced using program DINO [http://www.dino3d.org/].
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residues from the FWR L2. Similar to other Ab–Ag
complexes,27 the residues from the heavy chain,
particularly CDR-H2, make extensive contact with
Hyal. In the Hyal/Fab complex, 6 out of 17 Fab
residues interacting with Hyal are aromatic, in
agreement with a notion that aromatic residues,
particularly tyrosines, form most of the contacts
with Ag.27,38 Residues Tyr32 (L1), Tyr52 (H2) and
Tyr95 (H3) are almost completely buried (>90%)
within the interface, whereas Tyr49 (FWR L2), Tyr92
(L3) and Trp53 (H2) are partially buried (38–48%).
Apart from CDRs, residues Leu46 and Tyr49 from
FWR L2 are also involved in apolar interactions with
Hyal. The shape of the Ab binding cavity is similar
to those observed with haptens which bind in
grooves and pockets39 and usually do not cause
large conformational changes in Fab. The interaction
between residues from CDR-H3 and Hyal is
mediated by water and hydrophobic interactions.Discussion
We have identified the first B-cell epitope of Hyal,
a major allergen of bee venom, from the crystal
structure of Hyal in complex with the specific Fab
fragment of a monoclonal murine anti-Hyal IgG1
Ab. The Hyal epitope is composed of mostly
continuous array of nine residues folded as a
helix–turn–helix motive, which protrudes away
from the globular protein core and fits tightly into
the deep pocket formed by the six CDRs of the Fab.
A local conformational change of the turn joining
two helices is observed upon binding. Although the
epitope is continuous, its conformation is important
for Ab recognition, since a synthetic peptide
(Arg138–Glu152), comprising the entire epitope, isneither recognized by mAb-IgG 21E11 nor by
human IgE from the sera of bee venom allergic
patients. This is the second structural study of an
allergen–Ab complex after the major birch pollen
allergen Bet v 1 in complex with the Fab fragments
of a monoclonal murine IgG Ab.40 The latter
structure revealed a conformational epitope com-
posed of the 16 residues belonging to a rather flat
allergen–Ab molecular interface.
The IgE antibodies from allergic patients are
polyclonal and bind to several different epitopes of
an allergen. We have shown that mAb 21E11
exhibits a varying degree of inhibitory effect on the
binding of human IgEs to Hyal, ranging from 3% to
57% depending on the patient. This broad range of
inhibition efficacy probably reflects the different IgE
repertoire of each patient. The moderate inhibition
observed with most of the sera is probably due to
the presence of a variety of IgE antibodies which
recognize different epitopes. Thus, only a fraction of
IgE antibodies will be affected by the presence of
mAb 21E11 bound to Hyal. In the case that
inhibition is caused by direct competition of IgG
and IgE for the same epitope, the Hyal–IgG
interaction surface provides indirect information
on the interaction of Hyal with IgE. However,
allergen-specific IgG antibodies may inhibit the
binding of IgE by several alternative mechanisms,
such as (i) partial overlap of the IgG and IgE
epitopes, (ii) neighboring IgG and IgE epitopes
which cannot be occupied simultaneously due to
steric hindrance and (iii) perturbation of IgE
epitopes by the conformational changes induced
by IgG binding. The moderate inhibition (20–30%) is
consistent with the overlapping of IgG and IgE
epitopes, as well as with mechanisms (i) or (ii).
However, an inhibition of 57% would be consistent
either with the inhibition of a dominant IgE epitope
Figure 2. Hyal/Fab complex. (a) Ribbon representation of the Hyal/Fab complex structure. Same color code as in
Figure 1; Hyal is shown in magenta and Fab heavy and light chains are colored yellow and green, respectively. For clarity,
the residues of the Fab constant and variable domain not defined by electron density are also included and are colored
red. The polypeptide chain termini are labeled with N and C. (b) Conformational changes induced in the Hyal epitope
upon Hyal/Fab complex formation. Hyal, colored in magenta, is superposed on two models of unliganded Hyal: 1FCQ
(light reddish brown) and 1FCU (dark reddish brown). The largest Cα atom shifts (more than 2 Å) are seen for Phe143. (c)
Close-up view of the Hyal/Fab interface. The Hyal epitope is shown as a full atom representation colored magenta and
the molecular surface of the Fab colored yellow and green for the heavy and light chains, respectively. For clarity, residue
Arg138 of Hyal that is also involved in the interaction is not shown. For more details, see Table 4.
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affect a significant part of the molecule and thus
cause the simultaneous perturbation of several IgE
epitopes. However, the last proposed mechanism is
less likely because only a local conformational
change is observed.
The Hyal/Fab complex shares a number of
general features with other protein–Ab complexes
which possess a discontinuous epitope, e.g., all six
CDRs interact with the Ag,35,41 with the interactions
with the heavy chain being most prominent;27 the
contacting surfaces are highly complementary and
have areas in the range of 600Å2–900 Å2; the stability
of a complex is provided by van der Waals
interactions, hydrogen bonds and, to a lesser extend,
by salt bridges. Epitopes in most of the protein/
antibodies complexes are discontinuous and com-
prise 14–20 residues.35,41,42 In contrast, the Hyal
epitope is continuous and composed of only 9 resi-dues, thus resembling to an Ab–peptide complex.43
However, many conformational epitopes contain a
linear stretch of residues which account for most of
the interactions with specific antibodies. For exam-
ple, residues Ile42–Thr52 of the conformational
epitope of Bet v 1/Fab complex account for 80% of
all Ag–Ab interactions40 while residues 101–108 of
conformational epitope of extracellular domain of
myelin oligodentrocyte glucoprotein account for
65% of the total interaction surface of myelin oligo-
dentrocyte glucoprotein-extracellular domain.44
The Hyal/Fab complex contains four salt bridges,
between Asp145 and Arg148 of Hyal and Arg58
and Asp54 of Fab CDR-H2, respectively. Similarly,
in the lysozyme (likewise Hyal also an β(1,4)
glycosidase) in complex with Fab fragment of
specific Ab HyHEL-5, Arg45 and Arg68 of lyso-
zyme and Glu-H35 and Glu-H50 of Fab fragment
form three salt bridges.42 Both Hyal and lysozyme
Table 4. Hyal/Fab interaction: direct contacts
Fab Hyal Distance (Å)
Hydrogen bonds
CDR-L1 Tyr L32 OH Asp A146 OD1 3.1
CDR-L2 Asn L50 ND2 Arg A138 O 3.1
CDR-L3 His L91 NE2 Pro A142 O 2.9
Tyr L92 O Asp A146 N 3.0
Arg L96 NH2 Phe A143 O 2.7
CDR-H1 Gly H33 O Trp A144 NE1 3.2
CDR-H2 Tyr H52 OH Asp A145 N 3.1
Tyr H52 OH Asp A145 OD1 2.4
Arg H58 NH2 Gln A147 OE1 3.0
Salt bridges
CDR-H2 Arg H58 NE Asp A145 OD1 2.9
Arg H58 NH2 Asp A145 OD2 3.2
Asp H54 OD1 Arg A148 NH1 3.1
Asp H54 OD2 Arg A148 NH2 3.2
Apolar contacts
CDR-L1 Tyr L32 CZ Asp A146 CA 3.6
Tyr L32 CE1 Asp A146 CB 3.7
FWR2 Tyr L49 CD2 Pro A142 CB 3.5
Leu L46 CD2 Phe A143 CZ 3.6
CDR-L3 Tyr L92 CE1 Asp A146 CG 3.6
CDR-H1 Gly H33 CA Trp A144 CZ2 3.7
CDR-H2 Tyr H52 CZ Arg A148 CG 3.5
Trp H53 CZ3 Trp A144 CZ2 3.7
Trp H53 CH2 Trp A144 CZ2 3.5
CDR-H3 Tyr H95 CD1 Phe A143 CG 3.5
Tyr H95 CD1 Phe A143 CD1 3.6
The cutoff distance for polar contacts is 3.25 Å. The 11 van der
Waals interactions are shown for a cutoff value of 3.7 Å; increasing
the cutoff value to 4.0 Å results in 39 van der Waals contacts (not
shown).
Table 5. Hyal/Fab interaction: water-mediated contacts
Fab
Distance
(Å)
Water
molecules
Distance
(Å) Hyal
CDR-H3 Gly H97 N 3.1 21O 2.6 His A141
ND1
CDR-H1 Gly H33 O 2.7 21O
CDR-H2 His H50
NE2
3.1 22O 3.0 Phe
A143 O
CDR-L3 Gly L93 O 2.9 23O 2.7 Asp A145
OD1
CDR-L3 Arg L96
NE
3.1 23O
CDR-L3 Arg L96
NH2
3.2 23O
The cutoff distance is 3.25 Å.
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the cavity formed by VL and VH, which mediate
hydrogen bonding interactions between the two
proteins and their respective antibodies. In Hyal/
Fab complex, the CDR-H2 is involved in most of the
interactions with Hyal while CDR-H3 makes only
few contacts which are similar to those reported in
HyHEL-10 Fab–lysozymes complex.41Figure 3. Stereo view of the polar and ionic interactions wit
and 2. Hydrogen bonds (magenta) and salt bridges (cyan) a
shown in blue. For clarity, residue Arg138 of Hyal is not showThe shape of the Ag combining site of an Ab is
related to the nature of the Ag; deep pockets are
observed with haptens, grooves with peptides and
flat combining sites with proteins.39 It has been
shown that the lengths of the CDRs are directly
related to the topography of the Ag combining site
such that a longer CDR-H3 loop implies a flat or
protruding Ag combining site while a short CDR-H3
loop favors pockets or grooves.45 A deep binding
cavity is observed in the Hyal/Fab complex which
supports this hypothesis and agrees with the short
length of CDR-H3 (four residues). In contrast, the
epitopes of K+ channel/Fab complex and lyso-
zyme/HyHEL-10 Fab complex revealed a flat
interacting surface, in agreement with a longer
CDR-H3 loop consisting of 9 and 11 residues.41,46
The Hyal epitope has a central hydrophobic patch
which is surrounded by charge and polar residues.
The four salt bridges at the periphery of the Fab
binding cavity are probably involved in the initial
protein–protein association through long range
electrostatic interactions. In the following step, the
docking with the formation of specific interactionshin the Hyal/Fab complex. Same color code as in Figures 1
re shown as dashed lines. Water-mediated interaction is
n. For more details, see Tables 4 and 5.
‡www.genscript.com
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surface shows a good shape complementarity which
is enhanced by the presence of three water mole-
cules in the interface. Additional water molecules
are also observed at the periphery of the binding
cavity and are involved in hydrogen bonds which
are bridging Hyal with Fab. Similarly, Fv D1.3-HEL
and HyHEL-5–lysozyme complexes contain four
and seven water molecules which are located in
the cavity and mediate the hydrogen bonding
interaction.34,35
In more general terms, the structure of each new
Ag–Ab complex increases our knowledge and, hence,
the probability of identifying any features common
for Ag–Ab recognition, which would ultimately help
to reveal the characteristics of the allergen and the
underlying mechanism, which makes an Ag an
allergen. Attempts to predict features responsible for
allergenicity, either by the search for common
sequence motifs47,48 or a common motive on the
molecular surface,49 have recently been reported. The
latter revealed a high occurrence of solvent exposed
hydrophobic patches, which is in agreement with a
notion that the immune system has evolved to
recognize the hydrophobic portion of an immuno-
genic protein.50 Supporting this concept, the Hyal
epitope contains a surface-exposed hydrophobic
patch formed by loop residues Pro142–Phe143–
Trp144 which, upon complex formation, become
deeply buried in the interface. Similarly, the crystal-
lographically determined epitope of a major birch
pollen allergen Bet v 1 showed that the central part of
the conformational epitope consists of a linear stretch
of mostly apolar residues (P-loop region: Gly-Asn-
Gly-Gly-Pro-Gly-Thr) surrounded on both sides by
charged and polar residues.40
The Hyals from venoms of honey bee, Api m 2,
and wasp, Ves v 2, share 55% sequence identity and
have identical fold while the sequence variability is
mostly confined to the surface area.20 Of the nine
epitope residues of Hyal (Api m 2) only four are
conserved in Ves v 2. The central epitope residue
Phe143, which fits tightly in the hydrophobic pocket
formed by CDR residues of Fab, has been replaced
by a polar Thr residue in Ves v 2. Moreover, the
charge distribution among the non-conserved sur-
face exposed residues is significantly different and
hence, it is unlikely that the identified epitope is
responsible for the in vitro observed IgE-mediated
cross-reactivity between Api m 2 and Ves v 2. Since
both enzymes are glycosylated, it is possible that the
cross-reactivity can be mediated by carbohydrate
moiety, as suggested by Skov et al.20
Type I allergy is an IgE-mediated hypersensitivity
disease affecting up to 25% of the population of all
ages, from infants to the elderly. There is a definite
need for an effective treatment of this disease,
particularly for bee venom where the allergic
reaction to stings can occur suddenly with an
occasionally fatal outcome. The antigenicity of
Hyal is fully determined by the structure of its
epitopes, the areas of the protein surface that are
recognized by specific antibodies. The knowledgeof the Hyal epitope allows a structure-based
rational modification of the epitope surface aimed
at producing allergen variants with low IgE-
binding activity but able to induce protective
allergen-specific IgG antibodies which compete
with IgE (hypoallergens).51 The hypoallergens are
expected to have a significant impact on the devel-
opment of allergy vaccines with the increased safety
and efficacy for allergen-specific immunotherapy.Experimental Procedures
Protein expression and purification
Recombinant Hyal was produced as a secreted protein
by Baculovirus-infected insect cells (High Five) and
purified by Ni2+-chelate chromatography.13 The mono-
clonal hybridoma antibodies, derived from mice immu-
nized with recombinant Hyal, were purified from the
supernatants of hybridoma cells rich in specific IgG1
antibodies. To avoid any contamination with bovine IgGs
and serum albumin, a serum- and protein-free culture
media (TurboDoma) were used for the supernatant
production. The IgG1 antibodies purified by Protein G
Sepharose affinity chromatography were almost 100%
pure, as judged by SDS-PAGE and Coommassie Blue
staining (150 kDa under nonreducing conditions). The
purified IgG1 antibodies exhibited a high affinity to Hyal
and were able to compete with the binding of sera IgEs
from bee venom allergic patients.
Amino acid sequence of the complete variable light and
heavy chain of mAb 21E11 (murine IgG1, kappa) was
deduced from the cDNA sequence obtained by using RT-
PCR and the SMART race system (Clontech Laboratories).
The PCR products were cloned into TOPO vector (vector
with covalently bound topoisomerase I; Invitrogen) and
sequenced using M13 forward and reverse primers.
Synthetic peptide
The 15-mer peptide derived from the Hyal/Fab com-
plex (138-RREHPFWDDQRVEQE-152) and covering the
entire epitope sequence, was synthesized by Genscript
Corporation (Piscatway, NJ, USA)‡. The peptide was
purified by HPLC and verified by matrix-assisted laser
desorption/ionization time-of-flight mass spectroscopy.
The peptide was >80% pure and was fully soluble in
aqueous solutions.
ELISA
For ELISA experiments, the ELISA plates (Greiner,
Kremsmuenster, Austria) were coated overnight, at 4 °C,
with rApi m 2 (5 μg/ml dissolved in PBS) or the Api m 2
derived peptide 138-RREHPFWDDQRVEQE-152 (5 μg/ml
dissolved in PBS), and for control purposes with human
serum albumin (5 μg/ml in PBS) or a control peptide. The
plates were washed between each incubation step with
PBS containing 0.05% v/v Tween 20 (PBST). Non-specific-
binding sites were blocked with PBS/1% w/v bovine
serum albumin for 2 h at room temperature. Coated plates
750 X-ray Structure of Bee Venom Hyaluronidase/Fab Complexwere incubated with sera from bee venom allergic patients
(dilution 1:5) or the mouse mAb (dilution 1:1000) in PBS,
0.5% w/v bovine serum albumin, 0.05% v/v Tween 20;
both were added in duplicate and incubated overnight at
4 °C. Bound human IgE was detected as described.52
Bound mouse mAbs were detected with a monoclonal rat
anti-mouse IgG1 Ab (BD Pharmingen, San Diego, CA)
followed by the addition of horseradish peroxidase-
labeled goat anti-rat IgG antibodies (Amersham
Bioscience, Uppsala, Sweden) and visualized by the
addition of ABTS solution (60 mM citric acid, 77 mM
Na2HPO4×2H2O, 1.7 mM ABTS, 3 mM H2O2) as a
developer.
ELISA inhibition
ELISA plates were coated with 5 μg/ml rApi m 2
overnight at 4 °C. The plates were washed with PBST and
after blocking with PBST plus 1% w/v bovine serum
albumin, incubated overnight with three mouse mono-
clonal IgG1 antibodies against Api m 2 (21E11, 22H7,
24F2) or for control purposes, with a mouse mAb against
Bet v 1 (diluted 1:100). After washing, the plates were
incubated with 1:5 diluted sera from bee venom allergic
patients overnight at 4 °C and bound human IgE
antibodies were detected as described.52
Production of Fab fragments by papain
digestion of IgG
Purified Ab (clone 21E11, 3–6 mg/ml) was dialyzed
against 50 mM sodium acetate buffer (pH 5.5) containing
2 mM ethylene diamine tetra-acetic acid. Papain was
added (1/100 w/w ratio) in the presence of 10 mM freshly
prepared cysteine and digestion was carried out at 37 °C
for 6 h. The reaction was stopped by the addition of the
specific papain inhibitor E-64 (N-[N-(L-3-trans-carboxir-
ane-2-carbonyl)-leucyl]-agmatine) (Roche) in large excess.
The digestion mixture was dialyzed against 50 mM
sodium acetate buffer (pH 5.5), loaded on a Mono S
cation exchange column (Amersham Biosciences) and
eluted with a shallow salt gradient 0–150 mM NaCl. The
Fab was eluted at 70–80 mM NaCl and its purity was
confirmed by SDS-PAGE under both reducing and
nonreducing conditions. The Fab yield was about 30%
of the starting IgG1 amount. The purified Fab fragments
were mixed with Hyal in 1:1.2 molar ratio and incubated
at 23 °C for 60 min. The Hyal/Fab complex was sepa-
rated from excess Hyal by using a Superdex S-75 16/60
gel filtration column (Amersham BioSciences). The
protein concentration of the Hyal/Fab complex was
calculated from the absorbance measured at 280 nm,
assuming an extinction coefficient of 0.7 mg/ml−1 cm−1.
Crystallization and data collection
For the crystallization experiments, the purified Hyal/
Fab complex was dialyzed against 5 mM sodium acetate
buffer (pH 5.5) and concentrated to 11 mg ml−1. The
clusters of thin plate-like crystals were grown by the
hanging-drop vapor diffusion method within 4–5 days
under the following conditions: the equal volumes (1.5 μl)
of the Hyal/Fab complex and precipitant 10% (w/v)
polyethylene glycol (PEG) 8000, 0.1 M Ches (2-(N-
cyclohexylamino)ethanesulfonic acid) (pH 9.5), 0.2 M
NaCl (condition 29, Wizard screen kit I) were mixed and
equilibrated over the latter solution at 20 °C. The lowcrystal reproducibility was overcome by applying a
microseeding technique while the substitution of PEG
8000 (10%) by PEG 6000 (11%) resulted in a larger and
chunkier, but still clustered plate-like crystals. Prior to
data collection, single plates were separated, soaked
briefly in the cryoprotective solution (precipitant solution
plus 20% PEG 400) and the diffraction data were collected
to 2.6 Å resolution at Swiss Light Source (SLS), using a
MAR CCD detector (λ=0.9762 Å). All measurements were
performed at 100 K. The images were indexed and
integrated in a monoclinic space group C2 using the
program MOSFLM.53 There is one monomer of Hyal/Fab
complex per asymmetric unit, resulting in a solvent
content of 69% (Vm=3.95 Å
3/Da).54
Structure determination and analysis
The structure of the Hyal/Fab complex was determined
by the method of MR using the program PHASER.55 MR
was done in three steps. First, position and orientation of
Hyal were obtained using the monoclinic structure of
Hyal, 1FCQ13 as a search model. Second, the MR was
performed separately with variable, V, and constant, C,
domains of various Fab structures, in order to avoid dif-
ficulties related to the variable relative orientations of the
Vwith respect to the C domains of the search models. Out
of 30 different models, the V domain of 1A7Q gave a good
statistic and its position was fixed. Third, out of 18 C
domain models tested byMR, the PDB code 15C8 gave the
best statistics and its position was fixed. Rigid body
refinement with five domains (Hyal, VL, CL, VH and CH)
with REFMAC56 gave an initial R/Rfree of 36.0/39.1.
Manual adjustment of the model and replacement of the
model amino acid sequences with that of 21E11 Fab were
performed with program O.57 This was followed by re-
strained maximum-likelihood refinement with REFMAC
and addition of water molecules by the program ARP,
resulting in the convergence ofR/Rfree value to 20.9/24.7%
at 2.6 Å resolution.56 The stereochemistry of the refined
structure was validated with program PROCHECK,58
which showed that only 0.7% residues are in disallowed
regions of a Ramachandran plot (Table 3).
The buried surface area was calculated with program
MS59 using a probe radius of 1.7 Å. Interactions within the
Hyal–Fab interface were assigned with the program
CONTACT.56
Protein Data Bank accession codes
Coordinates and structure factors have been deposited
in the Protein Data Bank with accession codes 2j88 and
r2j88sf, respectively.Acknowledgements
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2.1.1 Hya/Fab complex formation, crystallization and diffraction
2.1.1.1 IgG purification
The supernatant  containing IgG was dialyzed (Spectra/Pro, membrane cutoff 12-14 
kDa) against 20 mM sodium phosphate buffer pH 7.0 and centrifuged at 13000 rpm (Sorval 
RC-5B, SLA-1500 rotor) for 30 min. The resultant  supernatant  was applied on a Protein-G 
affinity column (Amersham Pharmacia) that  specifically binds the Fc region of the IgG 
molecule. The bound IgG was eluted in 1 ml fractions with 100mM glycine buffer pH 2.7 
(Figure 1) and immediately neutralized with 200 μM of 1M Tris buffer pH 9.0. 
97.4
66.2
45.0
31.0
Heavy chain
Light chain
M      SM         1         2        3       4        5       6
Figure 1. IgG  purification. SDS-polyacrylamide gel (12%, reducing condition) 
analysis of the purified IgG eluted from Protein-G column. M stands for molecular 
weight markers (kDa), SM for starting material and fraction numbers are indicated 
at the bottom of the gel.  
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2.1.1.2 IgG digestion
The purified IgG was dialyzed  against 100 mM sodium acetate buffer pH 5.5 
containing 2 mM EDTA and was subsequently concentrated to 3-6 mg/ml using a centricon (30 
kDa molecular-mass cutoff; Amicon). To the concentrated IgG, freshly prepared cysteine was 
added to the final concentration of 10 mM and followed by the addition of papain at  the ratio of 
1/100 (W/W) with respect  to IgG concentration. The papain is an cysteine endopeptidase of 
23000 Da molecular weight  and was used for limited hydrolysis of native immunoglobulin (Ig). 
Digestion was carried out by incubating sample at 37 ˚C for 6 hours (Figure 2).  The IgG 
digestion was stopped by addition of 10 fold excess of E64 inhibitor (N-[N-(L-3-trans-
carboxyoxirane-2-carbonyl)-L-leucyl]-agmatine, Roche; Molecular weight 357.4 Da) relative 
to the papain concentration. The E64 stock has been prepared by dissolving the compound in 
1:1 ethanol/water mixture to the final concentration of 250 μM.
M   SM   1h    2h    3h   4h  5h   6h    7h     8h    10h
Undigested heavy chain
Fc
Fab
97.4
66.2
45.0
31.0
21.5
Figure 2. IgG test digestion. Digestion was carried out with papain in the presence of 10 
mM cysteine. SDS-polyacrylamide (12%, reducing condition) analysis of the digested 
sample collected at various time point as indicated at the bottom of the gel. M stands for 
molecular weight markers (kDa), SM for starting material. 
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2.1.1.3 Purification of Fab using cation exchange chromatography (Mono-S)
The digested sample was dialyzed against 50 mM sodium acetate buffer pH 5.5 and 
loaded on a cation exchanger (mono-S) column (Pharmacia) using acta purifier (Amersham 
Pharmacia). The long shallow salt  gradient  was carried out between 20 -120 mM NaCl in order 
to separate Fab isoforms from (Fab)2 (Figure 3). 
2.1.1.4 Complex formation and purification using gel filtration column (Superdex 
S-75 16/60)
The Fab, eluted as a major peak at  40 mM NaCl was pooled, mixed with hyaluronidase 
in 1:1.2 molar ratio and incubated at  room temperature for 1 hour. The Hya/Fab mixture was 
concentrated to 4-6 mg/ml using centricon (Amicon) and loaded on a Hiload Superdex S-75 
(Amersham Pharmacia) gel filtration column in order to separate Hya/Fab complex from excess 
Hya (Figure 4).
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Fab
Fc
(Fab)2
M  SM         B7   B6  B5 B4  B3  B1  C2  D11 D9 D7  D5 D3
97.4
66.2
45.0
31.0
21.5
14.4
Figure 3. Purification of Fab  using cation exchange chromatography (Mono-S column). A) 
Chromatogram of Fab elution profile. B) SDS-polyacrylamide (12%, non-reducing 
condition) analysis of proteins separated on Mono-S column. M stands for molecular 
weight markers (kDa) and SM for starting material. Fraction numbers are indicated at the 
bottom of the gel.  
A
B
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Figure 4. Purification of Hya-Fab  complex using Hiload 26/60 Superdex 75 16/60 gel filtration 
chromatography. A) Chromatogram show Hya/Fab  complex separated from excess Hya. B) 
SDS-polyacrylamide (12%, reducing condition) analysis of the first peak shows complex 
whilst the second peak shows an excess of Hya. M stands for molecular weight markers 
(kDa), SM for starting material and fraction numbers are indicated at the bottom of the gel.  
97.4
66.2
45.0
31.0
21.5
Hya
Fab
M Fab Hya SM D11 D9 D7 D6  D5 E2  E3  E4 E5  E6
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B
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2.1.1.5 Crystallization and diffraction
Hya/Fab - 21E11 complex:  The eluted Hya/Fab complex fractions were pooled, dialyzed 
against 10 mM sodium acetate buffer pH 5.5 and concentrated to 12-14 mg/ml concentration. 
The crystallization was performed with Hampton and Wizard screening kit Ⅰ and Ⅱ using 
hanging drop vapour diffusion method. The drops were prepared by mixing 1 μl of protein with 
1 μl of reservoir solution and equilibrated against 500 μl reservoir solution.  The Hya/Fab 
complex crystal were grown as clustered thin plates in 10 % PEG 8000, 0.1 M CHES pH 9.5 
and 0.2 M NaCl (condition 29, Wizard screening kit  Ⅰ) in 4-5 days (Figure 5). The crystals were 
not reproducible but  the microseeding helped to overcome the nucleation problem and 
subsequently crystals were grown in less than 24 hours. The crystal were cryoprotected with 
0.1M TABS pH 9.5, 11.5% PEG 8000 and 20 % PEG 400. Data was collected at  Swiss light 
source (SLS) and Hya/Fab complex crystal diffracted to 2.6 Å (Figure 6). 
Figure 5. Hya/Fab-21E11 complex crystals 
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Figure 6. Diffraction pattern of the Hya-Fab  complex. The images were recorded on a MAR-
CCD image plate detector. The crystal showed isotropic diffraction, with spots diffracting 
beyond 2.6 Å shown in the inset.
2.6 Å
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Hya/Fab-22H7 complex: The purified Hya/Fab complex was dialyzed against  10 mM sodium 
acetate buffer pH 5.4 and concentrated to 12 - 14 mg/ml. The crystallization was performed 
with commercial screens, that  is Hampton and Wizard screening kit  I and II using hanging drop 
vapour diffusion method. The drops were prepared by mixing 1 μl of protein with 1 μl 
reservoir solution and equilibrated against 500 μl of reservoir solution. The Hya/Fab 
(22H7.11.12) complex was crystallized in the presence of 9.5% PEG 8000, 0.1 M TABS pH 9.5 
and 0.2 M NaCl similar to 21E11.1.6 clone. The microseeding was applied to overcome the 
nucleation problem. The crystals were grown as thin plates and reached maximum size in 2-3 
days (Figure 7). 
Figure 7. Hya/Fab-22H7 complex crystals 
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2.1.1.6 Structure solution: Search for useful Fab model for molecular replacement 
(MR)
   The structure of Hya/Fab complex was determined by molecular replacement (MR) 
using the program PHASER [1]. The orientation and position of the Hya/Fab complex were 
determined by MR in three consecutive steps. First, Hya was located using PDB code: 1FCQ as 
a search model. On fixing the Hya position, PHASER gave a Z-score of 13. This was followed 
by rigid body refinement which gave Rfactor/Rfree of 41.8/42.5%. 
 The PDB database consists of more than 500 Fab structures. MR with intact  Fab model 
was not expected to work due to a rather various relative variable (VL and VH) and constant 
domains (CL and CH) arrangements. Therefore, the following strategy was applied to locate the 
correct Fab model from the database. Firstly, mass mapping was carried out  with light  and 
heavy chains separately and the sequence of top hits was used for Blast (NCBI BLAST). The 
Blast  with the heavy chain sequence gave the Fab (1S5I and 1ORS) and these Fabs were 
divided into variable (VL and VH) and constant domains (CL and CH) whilst the flexible linker 
region were removed. The MR was carried out in two steps; the position of the variable domain 
(VL and VH) was fixed followed by fixing the constant domain (CL and CH). The MR with 
variable domain of 1S5I and 1ORS gave good Z score of 18 and 20 and the R factor and Rfree of 
39.4/ 42.8% and 39.3/42.0% respectively. The structural neighbor to 1ORS heavy chain was 
searched using NCBI vast program and the results were sorted based on high redundant and 
root-mean square deviation (rmsd). For variable domain, four highest  hit (marked in pink) gave 
good statistics, out  of which, 1A7Q position was fixed and it gave Z score of 23 and Rfactor and 
Rfree of 37.8/41.6%. In total, 30 different  variable domain were used for MR. The variable 
domain consists of complementary determining regions (CDR) which is involved in antigen 
binding. The sequence and structure of CDR’s varies from one antibody to another. The 
position of CDR’s in 1A7Q were determined by Immunoglobulin (Ig) Blast  (NCBI Blast) and 
the truncation were made in CDR sequence i.e the occupancy of the corresponding amino acid 
was set  to zero, in order to exclude them from the refinement  using REFMAC [2]. The 
truncation in CDR’s of 1A7Q, improved the statistics to small extent  resulting in the Z score of 
24 and Rfactor/Rfree of 37.7/40.7%.
 Search for constant  domain models (CL and CH) was carried out randomly. Out  of 18 
constant  domain models, 15C8 gave a Z score 20. After five rigid body refinement (Hya, VL, 
CL, VH and CH) the Rfactor/Rfree was 36.0/39.1%. The density for the terminal region of 
constant  domain was not well defined. Thus, Hya, variable and constant  domains had been 
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found representing the full Hya/Fab complex structure. Manual adjustment of the model was 
performed with program O [3] and was followed by full atom refinement that gave an Rfactor/
Rfree of 26.9/31.2%. Replacement of the model amino acid sequences with that  of 21E11 Fab 
was performed with program O and followed by refinement with REFMAC converged Rfactor/
Rfree to 21.0/24.7% at 2.6 Å. 
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2.1.1.7 Hya/Fab-21E11 crystal packing
Hya/Fab complex crystallized in C2 (monoclinic) space group, which contains two fold 
rotation along b-axis and c-centering on ab plane. The C2 space group consists of four 
asymmetric units. In case of Hya/Fab complex, each asymmetric unit  contains one Hya/Fab 
complex. The crystal contacts are mediated by Hya-Hya and Hya-VH contacts.
Figure 8. Schematic representation of a search for the Hya/Fab  model by molecular 
replacement (MR). The number of search models, model with PDB  code, Rfactor and  Rfree 
values, used at various stages of MR are indicated in box. The method used for finding the 
useful variable domain model is showed on the left.
Figure 9. Crystal packing of Hya/Fab-21E11 complex. Magenta represents Hya, yellow 
heavy chain and green light chain). The picture was produced using the program DINO 
(A.Philippsen, http://www.biozentrum.unibas.ch/~xray/dino).
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2.1.2 Mechanism of Type 1 hypersensitivity reaction.
Allergy caused by insect venom is an example of immediate type 1 hypersensitivity reaction. In 
genetically susceptible individual, some environmental protein antigen, commonly called 
allergen, can stimulate distinct immune response. They preferentially use particular antigen 
presenting cells (APC) such as dentritic cells and B cells and stimulate CD4+ T  cells to 
differentiate into Th2 effector T cells. The activated Th2-type cells produce cytokines - such as 
interleukin-4 (IL-4) and IL-13 - which promote switching of B cells to IgE producing plasma 
cells, whilst IL-5 stimulates eosinophilic survival and activation (Figure 10). In addition to 
cytokines, various other factors influence the differentiation of CD4+ T  cells into the Th2 
phenotype, such as the genetic background of the individual, the site of antigen contact, 
allergen dose and conformation, the nature and number of antigen presenting cells, as well as 
inflammatory mediator (e.g. histamine) [4]. In addition, immune cells recognize allergen 
epitopes differently: T-cells recognize continuous amino acid sequences (i.e. continuous 
epitopes), whereas B cells recognize allergens in there intact three dimensional structure (i.e. 
conformational epitope). The secreted IgE circulates throughout the body and binds to high-
affinity Fc receptors FcεRI  on the surfaces of circulating basophils and on mast cells in 
various tissues. This primary response to allergen is known as sensitization. 
On second re-exposure, multivalent  antigen binds to the cell-associated IgE and cross-
links two or more IgE molecules bound to the Fc receptors. This leads to a series of signaling 
events in the mast cells and basophils, which result  in the release of preformed mediators, such 
as histamine and leukotrienes, stored in the cytoplasmic granules. The clinical and pathologic 
manifestations are due to the actions of the released mediators. Some of these mediators induce 
an immediate symptoms of disease, such as rhinitis, conjunctivitis, vascular and smooth muscle 
reaction and asthma, and others stimulates the influx of leucocytes resulting in the late phase 
reaction [4-6].   
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Figure 7. Mechanism of Type 1 allergic reaction. a) Sensitization and memory. Initial contact 
with allergen, might favour allergen uptake by potent antigen presenting cells (APC) and/or 
immunoglobulin mediated capture by B cells. The activated T helper 2 (Th2) cell produce 
the cytokines such as interleukin-4 (IL-4) and (IL-13) that favour immunoglobulin-class 
switching of specific B  cells to immunoglobulin E (sensitization). The secreted IgE binds to 
specific receptors (FcεRI, high affinity receptor; FcεRII, low affinity receptor) on to mast 
cells, basophils etc. Sensitization leads to the establishment of IgE memory B cells and 
allergen specific memory T cells. , B. Immediate reaction. The cross linking of effector cell 
bound IgE by allergens leads to the degranulation of cytoplasmic granules which contains 
biologically active mediators such as histamine, leukotrienes etc. These released mediator 
are responsible for the immediate symptoms of allergy. C. Late reaction. This is caused by 
the presentation of allergens to T cells, which become activated, proliferate and release 
proinflammatory cytokines such as IL-4, IL-5 and IL-13. IL-5 induce tissue eosinophilia and 
the release of inflammatory mediators from eosinophils. This process might be enhanced by 
the IgE mediated presentation of allergen to T cells This picture has been taken from 
Valenta R 2002 [4]. 
2.1.3 Specific immunotherapy (SIT) 
 Allergic disease affect  more than 30% of the population in industrialized countries, 
with an increasing prevalence during the last  decades. Currently, SIT  is performed with natural 
allergen extracts that are not designed for an individual patient’s allergen profile. Besides, they 
contain various allergenic, as well as non-allergenic components and might  even be 
contaminated with allergen from other sources. In general, successful SIT  requires high dose of 
allergen extract and in most cases, required dose could not  be achieved due to the development 
of severe systemic side effects including anaphylactic reaction [4]. 
 Rapid development in the field of recombinant  allergens revealed the molecular nature 
of many important  allergens and facilitated the characterization of their immunological and 
structural features. This knowledge allowed modifying allergen to contain relevant T-cell 
epitopes that induce T-cell tolerance and lack antibody-binding sites (hypoallergen) that would 
otherwise facilitate IgE-mediated allergic responses. The hypoallergenic proteins have 
diminished or no IgE binding activities thus enabling the administration of high allergen doses 
with a reduced risks of systemic side effects. Such hypoallergenic allergen derivatives have 
been generated by modifying the allergen encoding cDNA (e.g. mutation, deletion, 
oligomerization and production of hybrids) [7].
   Most  direct  method to map IgE binding epitopes is the structure determination of 
allergen in complex with Fab fragment  of IgG antibodies that  compete with patient sera IgE 
antibodies in binding to Hya. The hypoallergenic allergens were generated by destroying the 
epitope either by introducing mutation or deletion of epitope residues. In case of birch pollen 
allergen Bet v1, single mutation in the mapped epitope showed 50% reduction in the binding of 
human polyclonal IgE [8]. The chimeric protein major bee venom allergens (Api 1/2/3), 
induced 100 to 1000 times less type-1 skin test  reactivity in allergic patients. Moreover, 
treatment in mice with chimeric protein led to significant  reduction of specific IgE 
development  towards native allergen, representing a protective vaccine effect in vivo [9].  The 
clinical trial with peptides containing only T-cell epitopes (peptide immunotherapy, PIT) to 
major cat  allergen, Fel d 1 [10] and bee venom major allergen, phospholipase A2 [11] showed 
beneficial modulation of immune response against whole allergen. 
Though numerous clinical studies documented the efficacy of immunotherapy, but the 
underlying immunological mechanisms remains a matter of controversy. Most  likely, several 
different  mechanisms were involved in the observed long term effects of immunotherapy. 
                                                                               Hya/Fab-supplementary information
40                                                                           
Moreover, the importance of blocking antibodies has been questioned because it was not 
always associated with clinically successful immunotherapy [4].
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3.0  Purification and biophysical characterization of bo-
vine testes hyaluronidase (PH-20)
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3.1 Abstract 
PH-20 is well characterized mammalian hyaluronidase, present  on the sperm plasma 
membrane and inner acrosomal membrane via GPI-anchor and plays important  role in fertiliza-
tion. It  is a bifunctional protein: N-terminal domain carrying hyaluronidase activity involved in 
cumulus penetration, while the C-terminal is presumably involved in binding of acrosome re-
acted (AR) sperm to the zona pellucida. In the present study, we were able to purify PH-20 pro-
teins from commercial available bovine testicular extract (Sigma) and from fresh bovine testes 
to highest  purity. PH-2060 purified from commercial source is probably endoproteolytic cleav-
age product whereas PH-2069 (Sigma) and PH-2080 (bovine testes) are intact protein. The puri-
fied PH-20 proteins forms heterogeneous aggregate, most likely by hydrophobic interaction, 
which was successfully overcomed by addition of zwitterionic compound, NDSB (non deter-
gent sulfobetaine).
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3.2 PH-20/Sperm adhesion molecule (SPAM1) 
PH-20 was first  identified as a ‘spreading factor’ based on the spreading properties ex-
hibited by the extracts from mammalian testes.[1]. Initially, the zona pellucida recognition 
function of PH-20 was discovered on the guinea pig sperm [2, 3]. Later, when the bee venom 
hyaluronidase was cloned, a marked cDNA sequence homology with PH-20 was recognized 
[4], and it is now apparent that PH-20 is the hyaluronidase of mammalian sperm. 
PH-20 is a bifunctional protein, composed of the N-terminal domain carrying hyalu-
ronidase activity involved in cumulus penetration [5], while the C-terminal could be involved 
in binding of acrosome reacted (AR) sperm to zona pellucida [2, 3]. PH-20 is glycosyl phos-
phatidylinositol (GPI)-anchored on the plasma membrane and inner acrosomal membrane 
(IAM) of the sperm through C-terminal end [6, 7]. In most  mammals, the membrane bound PH-
20 proteins are released by treatment with phosphatidylinositol-specific phospholipase C (PI-
PLC) [5, 7, 8], whereas 80-kDa protein carrying hyaluronidase activity present on the surface 
of the bull spermatozoa was not released by PI-PLC treatment [9].
PH-20 proteins from various mammals shares approximately 50-60 % sequence iden-
tity. It has number of potential N-glycosylation sites but  more interestingly, 12 cysteine resi-
dues are highly conserved among PH-20 proteins (Figure 1). PH-20 consists of N- and C-
terminal signaling sequence which are removed upon maturation. The length of the N-terminal 
signaling sequence is about  35 residues based on N-terminal sequencing of the matured protein. 
Hyaluronidase domain of PH-20 may account for 350 residues based on sequence similarity 
with bee venom hyaluronidase. The length of the zona pellucida binding domain is approxi-
mately 110-130 residues. PH-20 has potential GPI-anchoring site at  the C-terminal end in mon-
key, human and guinea pig, while bovine, mouse and rat PH-20 sequence lack the potential site. 
The potential active site residues Asp111 and Glu113 have been proposed based on mutagene-
sis studies on human PH-20 hyaluronidase [10] which was later confirmed by the crystal struc-
ture of bee venom hyaluronidase in complex with HA-tetramer which enabled the elucidation 
of the hyaluronidase catalytic mechanism [11]. Structural features established by disulfide 
bonds and glycosylation are essential for hyaluronidase activity of PH-20 protein [12]. The 
predicted isoelectric point  of bovine PH-20 protein is 8.56, which is based on the sequence ob-
tained from Meyer et al., 1997 [13].
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Fertilization is a complex process; which results in the fusion of sperm and egg. An 
ovulated mammalian egg is enclosed by two layers, an outer layer consists of cumulus cells 
embedded in extracellular matrix rich in hyaluronic acid and an thick inner layer which is zona 
pellucida. For fertilization to occur, sperm must penetrate both layers in steps requiring sperm 
motility, sperm surface enzymes, and probably secreted acrosomal enzymes [14-16] (Figure 2). 
Since cumulus cells are embedded in the extracellular matrix abundant in hyaluronan, a GPI-
anchored sperm hyaluronidase, PH-20, thus enables the penetration of acrosome intact  (AI) 
sperm through cumulus mass [4, 5, 17]. In addition to hyaluronan hydrolyze, PH-20 protein is 
believed to be involved in the binding of acrosome reacted (AR) sperm to zona pellucida [2, 3]. 
Then acrosome reacted spermatozoa deprived of membrane penetrate through the zona pellu-
cida and reach the egg’s plasma membrane, where binding and fusion of the gametes take 
place. In support of this proposal, the immunization of guinea pigs with PH-20 results in 100% 
contraception of both male and female, the effect being long-lasting and reversible [18].
Mammals consists of two PH-20 variants, the lower molecular weight  isozyme is be-
lieved to be produced by endoproteolytic cleavage of the larger protein during the acrosomal 
reaction. PH-20 has variable pH optima: high molecular weight  isozyme has broad range with 
the highest activity at  neutral pH (pH 7.0) [7, 9], whereas lower molecular weight isozyme ex-
hibits hyaluronidase activity only at  acidic pH (pH 4.0) [7]. Amino acid sequencing of lower 
molecular weight bovine testis PH-20 protein lacks the signal peptide at the amino terminus 
and 56 amino acids at  the carboxyl end in comparison to mature protein. This strongly suggests 
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Figure 1. Multiple sequence alignment of PH-20 proteins. The proteins listed from top  to bot-
tom: bovine PH-20 (residues 1-534, sequence obtained from Mayer et al 1997), bovine PH-20 
fragment (1-474, NCBI accession number Q7YS45), human PH-20 (1-509, P38567), monkey 
PH-20 (1-510, P38568), mouse PH-20 (1-512, P48794), rat PH-20 (1-512, Q62803) and 
guinea pig PH-20 (1-529, P23613). Fully conserved residues shown in red box with white 
character and partially conserved residues shown in red character. Domains are marked as 
lines with different color on the top  of the alignment: orange represent N-terminal signaling 
sequence, blue represent hyaluronidase domain, pink represent zona pellucida binding do-
main and green represent C-terminal signaling sequence. Blue arrowheads denote the active 
site residues Asp111 and Glu113. Green arrowhead represent conserved cysteine residues. 
Six potential N-glycosylation sites of bovine PH-20 protein are indicated by (?) on the top  of 
the sequence alignment.
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that  the lower molecular weight  form is generated by proteolysis, probable by the action of ac-
rosomal enzymes [13].
In addition to fertilization, mammalian hyaluronidases plays important  role in many 
biological process but  the study of these enzymes are greatly neglected. In the present  study, we 
purified PH-20 protein from bovine testicular extract (Sigma) and bovine testes to homogeneity 
and characterized them.
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3.3 Material and methods
3.3.1 Substrate gel assay
Hyaluronic acid substrate gel electrophoresis was performed according to the protocol 
described by Guntenhoener et al., 1992 [19]. The protein was subjected to electrophoresis un-
der non-reducing condition on 12% (w/v) SDS-PAGE gel copolymerized with 0.17 mg/ml of 
hyaluronic acid. The gel was incubated in the TBS buffer (20 mM Tris-HCl, pH 7.5 150 mM 
NaCl) containing 3% (v/v) TritonX-100 for 3 hours at room temperature on a rocking platform 
to remove SDS and then in 100 mM sodium acetate buffer pH 4.0, for 14 to 16 hours at 37˚C. 
To visualize digestion of hyaluronic acid, gels were stained with 0.5% (w/v) alcian blue in 3% 
(v/v) acetic acid for 2 hours at room temperature and destained in 7% (v/v) acetic acid. The 
presence of activity in the gel was revealed by a lack of coloration of a digested area against  the 
blue background characteristic for undigested hyaluronic acid.
3.3.2 Protein Electrophoresis and Immunoblotting
Protein samples were solubilized in sample buffer (62.5 mM Tris-HCl pH 6.8, 10% 
glycerol, 2% (w/v) SDS, 0.01% (w/v) bromophenol blue with or without 100 mM DTT) and 
heated at 99˚C for 3 min and separated on 12% SDS-PAGE [20]. 
The immunoblotting was done according to standard protocol (Molecular cloning, 
Sambrook et al., 2nd edition). After electrophoresis, the protein was transfered onto a nitrocel-
lulose membrane  (BA85, Schleicher & Schuell, Dassel, Germany) using Bio-Rad PROTEAN 
2 Electrophoresis / Mini Trans-Blot Module. The transfer was carried out in the presence of 
blotting buffer (20 mM Tris buffer pH 8.3, 150 mM glycine and 20% methanol) at  100V, 4˚C 
for 1 hour. The transferred membrane was blocked with TTBS buffer (20 mM Tris pH 7.4, 150 
mM NaCl, 0.1% (v/v) Tween 20) containing 5% (w/v) dry skim milk to prevent non-specific 
binding. The membrane was incubated with TTBS buffer (with 5% (w/v) dry skim milk) con-
taining primary antibody, ram PH-20 polyclonal antibody (Babraham bioscience technologies) 
at  dilution 1:2500 for 1 hour in room temperature. Subsequently, the membrane was washed 
with TTBS for three times at  the interval of 10 minutes and then incubated with TTBS (with 
5% (w/v) dry skim milk) containing secondary antibody, anti-mouse IgG antibody-peroxidase 
conjugate (Sigma) at 1:5000 dilution for 1 hour at room temperature.  Again, the membrane 
was extensively washed in TTBS as described before and incubated in ECL Western blotting 
detection reagents according to manufacturers protocol (Amersham Biosciences). The blot  was 
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subsequently exposed to KodakX-OMAT  XAR-5 radiography film for 15 sec to 15 min until 
the positive bands were visualized by enhanced chemiluminescence.
3.3.3 Cloning and expression of human PH-20
Cloning and expression of PH-20 fragment (1-332) containing a C-terminal 6xHis tag 
was carried out  by Dr. Margit  Schmidt, Department of Biology, East Carolina University. Hu-
man PH-20 gene comprising amino acids Leu1 to Ile332 was ligated into the Pichia expression 
vector pPICZαA (Invitrogen) and transformed into TOP 10 E. coli cells (Invitrogen). The 
plasmid was purified and transformed into Pichia pastoris strains X33 and KMH71H using 
10μg plasmid. From each strain ten single colonies were isolated, cultured in complex liquid 
media and expression was induced by the addition of methanol. The harvested culture super-
natant  and the cell extract from positive clones were analyzed for expression in our laboratory 
by SDS gel electrophoresis, anti-His antibodies and substrate gel assay. 
3.3.4 Protein purification from crude extract (type Ⅳ-S: From bovine tes-
tes, Sigma)
The PH-20 was purified according to the modified procedure described elsewhere [9, 
13, 21, 22]. Lyophilized crude extract (type Ⅳ-S: From bovine testes, Sigma) was dissolved in 
20 mM sodium phosphate buffer pH 7.0 and purification was carried out  as a six step proce-
dure. As a first  step the ammonium sulfate was added slowly to reach 45% saturation by con-
stant  stirring using magnetic bead (Heidolph MR 3001) for 4 to 6 hours at 4˚C. This was fol-
lowed by centrifugation at  13000 rpm for 30 min at  4˚C (Sorval RC-5B) and the precipitant 
was removed. To the supernatant  ammonium sulfate was added to reach 70% saturation by con-
stant  stirring for 4 to 6 hours followed by centrifugation of mixture at  13000 rpm for 30 min at 
4˚C. The precipitate obtained between 45-70% saturated ammonium sulfate was rich in PH-20 
(monitored by Western blot analysis and substrate gel as described earlier), dissolved in 20 mM 
sodium phosphate pH 6.0 and dialyzed (Spectra/Pro, membrane cutoff 12 - 14 kDa) against  the 
same buffer. The insoluble precipitate formed during the dialysis was removed by centrifuga-
tion at 13000 rpm for 30 min and resultant  supernatant  was loaded on a Resource Q anion ex-
changer column (Amersham Pharmacia) using acta purifier (Amersham Pharmacia). PH-20 
elutes in flow through (monitored by substrate gel) whereas many contaminant  proteins bound 
to Resource Q resin were eluted with 20 mM sodium phosphate pH 6.0 containing 1 M NaCl. 
The flowthrough was dialyzed against  20 mM sodium phosphate pH 7.0 and applied onto 
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Protein-G affinity column (Amersham Pharmacia) to separate immunoglobulins. The PH-20 
found in flowthrough was concentrated using centricon (Amicon Ultra, membrane cutoff 30000 
kDa) and applied on a Mono-S cation exchanger column (Pharmacia). The PH-20 was bound to 
the Mono-S column and eluted with 20 mM sodium phosphate buffer pH 7.0 containing 1 M 
NaCl as step gradient. The fractions containing PH-20 (identified by substrate gel and mass 
mapping), were concentrated and applied to Hiload 26/60 Superdex G-75 (Amersham Pharma-
cia) gel filtration column. Protein concentration of purified PH-20 was determined by absorp-
tion spectroscopy (Hewlett  Packard 8453, HP845X UV-Visible system, Switzerland) at  280 nm 
using extinction coefficient  of 89435 (lower species) and 90430 (higher species) M-1 cm-1 cal-
culated from the amino acid sequence obtained from Mayer et al., 1997. The extinction coeffi-
cient was calculated using ProtParam (http://www.expasy.org/tools/protparam.html) from Ex-
pasy server.
3.3.5 Protein purification from bovine testes
Fresh bovine testes were obtained from regional slaughterhouse and stored at  -80˚C. 
When needed, frozen testes were thawed overnight at  4˚C. Outerlayer of the testis was re-
moved, the inner layer cut  into small pieces and homogenized using buffer (20 mM sodium 
phosphate pH 7.0) containing protease inhibitor (1 mM EDTA, 10 μM Leupeptin, 1 mM 
PMSF) at  4˚C. Homogenized sample was centrifuged at  8000 rpm for 30 min at 4˚C and pellet 
was removed. To the supernatant ammonium sulfate was added slowly to reach 40 % saturation 
by constant  stirring for 4 to 6 hours in the cold room. The sample was then centrifuged at 8000 
rpm for 30 min and pellet  was removed. To the resultant supernatant  ammonium sulfate was 
added slowly to reach 70 % saturation by constant  stirring for 4 to 6 hours followed by cen-
trifugation at 8000 rpm for 30 min. The pellet obtained from 40 - 70 % saturation was dissolved 
and dialyzed against 20 mM sodium phosphate buffer pH 6.0. 
To handle large volume in each step of purification, ion exchange column was packed 
manually with Q sepharoseTM fast flow (Amersham Biosciences) and SP sepharoseTM fast  flow 
(Amersham Bioscience) beads separately. Dialyzed sample was applied on the anion exchanger 
(Sepharose-Q), PH-20 elutes in flowthrough whereas most  contaminant were bound to the col-
umn. The collected flowthrough was dialyzed against  20 mM sodium phosphate pH 7.0 and 
applied on a Protein-G column, which bound the immunoglobulins whereas PH-20 eluted in 
flowthrough. The collected supernatant was applied on a cation exchanger (Sephrose-S) and 
bound proteins where batch eluted with 20 mM sodium phosphate pH 7.0 containing 30, 120, 
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200, 1000 mM NaCl. The fractions containing PH-20 (monitored by substrate gel and mass 
mapping) were pooled and applied onto Hiload 26/60 Superdex G-75 (Amersham Pharmacia) 
gel filtration column. The concentration of the higher species of PH-20 protein was determined 
by absorption spectroscopy (Hewlett  Packard 8453, HP845X UV-Visible system, Switzerland) 
at  280 nm using extinction coefficient  of 90430 M-1 cm-1 calculated from the amino acid se-
quence.
3.3.6 Analytical ultracentrifugation 
The sedimentation equilibrium (SE) and sedimentation velocity (SV) were performed 
on a Beckman optima XL-A analytical ultracentrifuge (Beckman Instruments) equipped with 4 
and 12 mm Epon double sector cells. The experiments were carried out in the presence and ab-
sence of NaCl and with the presence of dimethylammonium sulfonate (Zwitterionic com-
pound). Sedimentation velocity runs were carried out at two different speeds 44000 and 52000 
rpm at  20˚C and the sedimentation coefficients were corrected to standard condition (water, 20 
˚C). Sedimentation equilibrium measurements were carried out  at  20 ˚C at rotor speeds from 
5000 to 7000 rpm using 12-mm double sector cells filled with 0.1 ml solution. Molecular 
masses were evaluated in sedimentation equilibrium experiments from ln A versus r2 plots, 
where A represents the absorbance and r is the distance from the rotor center. A partial specific 
volume of 0.73 cm3/g was assumed in all calculations. The molecular masses were calculated 
using the Segal computer program (www.biozentrum.unibas.ch/auc). All the analytical ultracen-
trifugation experiments were performed by Ariel Lustig, Biozentrum, University of Basel. 
3.3.7 Mass spectral analysis 
The mass spectrometry experiments were performed by the group of Dr. Paul Jenoe, 
Biozentrum, University of Basel as described [23, 24]. Liquid chromatography (LC) / Mass 
spectrometric (MS) analysis of the protein and its digest  was carried out  on 100 μm i.d.(inner 
diameter) capillary column packed with C18 Monitor-Spherical silica (5-μm particle size, Col-
umn Engineering Inc., Ontario, CA). The bound peptide were eluted with 0.05% trifluoroacetic 
acid to 60% acetonitrile containing 0.05% trifluoroacetic acid at  the flow rate of 1-2 μl/min. 
The outlet of the column was directed to a microspray needle, which was pulled from 100 μm 
i.d.(inner diameter) × 280 μm o.d. (outer diameter) fused silica capillaries (LC Packings) on a 
model P-2000 quartz micropipette puller (Sutter Instruments Co.). The needle was placed into 
an XYZ micropossitioner, and the voltage was applied directly to the sample stream through 
the capillary union. Spray voltages were usually between 1100 and 1400 V. Mass determina-
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tions were carried out  on a TSQ7000 triple quadrupole mass spectrometer (Finnigan, San José, 
CA). All measurements were carried out in the positive ion mode. Precursor ion scanning was 
between 200 and 2000 Da for 3 s at unit resolution. For operation in the MS/MS mode, the 
resolution of Q1 was set  to transmit  a mass window of 4 Da and the resolution of Q3 was ad-
justed to 1.5 Da. Scanning was between 50 and 2250 Da in 3.5 s. Argon was used as a collision 
gas at a pressure of 3.5 mTorr. 
3.3.8 Mass fingerprinting
The protein bands corresponding to PH-20 were cutout of the SDS/PAGE gel and incu-
bated with trypsin (sequencing grade, Promega) at 37˚C for 2 h. Trypsined fragments were de-
salted on C18 ZipTips (Millpore) and eluted with 1.5 μl 80% acetonitrile, 0.1% TFA, contain-
ing 1μl/ml α-cyano-4-hydroxycinnamic acid (Aldrich). About 300 nl of the elute was deposited 
onto anchor spots of a Scout  400 μm/36 sample support (Bruker Daltonik, Germany) and the 
droplet was left to dry at  room temperature. Mass spectra were recorded on a Bruker Scout  26 
Reflex Ⅲ instrument (Bruker Daltonik). The instrument  was calibrated with angiotensin Ⅱ, sub-
stance P, bombesin, and adrenocorticotropic hormone. Peptides were analyzed in reflector 
mode using delayed ion extraction with a total acceleration voltage of 23 kV. The molecular 
weights of the each ejected peptide fragment were measured and searched in the sequence li-
brary using the programme MASCOT. 
3.3.9 Crystallization attempts 
Two different molecular weight  species purified from Sigma crude extract were dia-
lyzed against  5mM sodium acetate pH 4.0, concentrated using centricon to 4.3 mg/ml (lower 
species) and 8.3 mg/ml (higher species), respectively. PH-20 purified from bovine testes 
(higher species) was dialyzed against  20 mM HEPES pH 7.0 and concentrated to 10 mg/ml. 
Crystallization was performed with concentrated protein solutions using Hampton screen kits Ⅰ 
and Ⅱ by hanging drop vapour diffusion method. The drops were prepared by mixing 1 μl of 
protein with 1 μl of reservoir solution and equilibrated against 500 μl of reservoir solution.
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3.3 Results
3.3.1 Expression of recombinant human PH-20 protein
The attempts to clone and express the N-terminal hyaluronidase domain of PH-20 
(residue Leu1-Ile312) in Pichia pastoris were not successful. Unfortunately, PH-20 protein 
expression was neither detected in the supernatant  nor in the cell extract. Cloning and 
expression of the same PH-20 fragment in Baculovirus was also not  successful (data not 
shown). All these experiments were performed by Dr. M. Schmidt.
3.3.2 Purification of PH-20 protein from Sigma crude extract
Since the human PH-20 protein could not  be expressed successfully in Baculovirus and 
Pichia pastoris expression systems, an attempt  was made to purify PH-20 from commercial 
bovine testicular crude extract (type Ⅳ-S, Sigma).
The PH-20 purification comprised of six steps (see PH-20 purification scheme, Figure 
3). In each step of purification, PH-20 protein was monitored by one or more of the following 
methods: 1) substrate gel electrophoresis assay, 2) Western blot  analysis using a polyclonal ram 
anti PH-20 antibody, and 3) MALDI mass mapping of tryptic fragments. 
Lyophilized crude extract (Sigma) was dissolved and fractionated by ammonium 
sulfate precipitation. The resultant fractions were analyzed by SDS/PAGE and Western blot 
(Figure 4). The hyaluronidase rich pellet obtained with 45-70% saturated ammonium sulfate 
precipitation (Figure 4B).
The PH-20 rich precipitant was dissolved and dialyzed against  20 mM sodium 
phosphate buffer pH 6.0. The sample was loaded on an anion exchanger (Resource Q) where 
PH-20 eluted in the flowthrough while some major contaminants remained bound to the 
column (Figure 5B). The substrate gel of the flowthrough sample showed strong hyaluronidase 
activity corresponding to two different molecular weight proteins, whereas the elution sample 
showed less activity (Figure 5C).
The flowthrough from Resource Q column, in addition to PH-20 contained 
immunoglobulin as one major contaminant as determined by MALDI mass mapping. The 
sample was dialyzed against  20 mM sodium phosphate pH 7.0 and applied onto a Protein-G 
affinity column. PH-20 eluted in flowthrough as confirmed by the substrate gel and the 
immunoglobulin remained bound to the column (Figure 6).
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A. Partially purified bovine testes 
crude extract ( Sigma)
B. Bovine testes
Homogenized using 20mM sodium phosphate buffer pH 7.0 
containing 1mM EDTA, 1μM Leupeptin, 1mM PMSF
Centrifuged at 8000 rpm for 30 min
PelletSupernatant
Step 1: Ammonium sulfate fractionation (45% saturation)
Centrifuged at 13000 rpm for 30 min
Centrifuged at 13000 rpm for 30 min
Pellet Supernatant
Dissolved and dialyzed against 20mM 
sodium phosphate buffer pH 6.0
Step 3: Anion exchanger Resource-Q (Sigma) or  Q sepharose (bovine testes)
ElutionFlowthough 
Dialyzed against 20mM sodium phosphate buffer pH 7.0
Step 4: Protein-G affinity column
Flowthough Elution
Step 5: Cation exchanger Mono-S column (Sigma) or SP sepharose (bovine testes)
Flowthough PH-20 elutes between 70 - 120mM NaCl (Mono-S)
PH-20 batch eluted with 120 mM NaCl (SP sepharose)
Concentrated with centricon
Step 6: Gel filtration (Hiload Superdex S-75 26/60) column
Pure PH-20
Dissolved in 20mM sodium 
phosphate buffer pH 7.0
Step 2: Ammonium sulfate fractionation (70% saturation)
PelletSupernatant
?
?
?
?
?
?
Figure 3. PH-20 purification scheme. A) From partially purified bovine testes crude extract 
(Sigma). B) From fresh bovine testes.
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The flowthrough from the Protein-G column was applied onto a cation exchanger 
(Mono-S) column. It  was found that  PH-20 bound to the column and eluted between 70-120 
mM NaCl (Figure 7). At this stage of the purification, the majority of the contaminant  proteins 
were removed and PH-20 migrated in SDS-PAGE as two different molecular weight  proteins 
with the molecular weight of approximately 60 kDa (PH-2060) and 69 kDa (PH-2069) (Figure 7 
B). The MALDI mass mapping of two different molecular weight  protein bands, cutout from 
the lane D3 matched to bovine testicular hyaluronidase (AAP55713) (shown in figure 12). 
The fractions containing PH-20 were pooled, concentrated and subjected to gel 
filtration chromatography (Hiload Superdex S-75 26/60). Two different molecular weight 
PH-20 proteins were partially resolved and several lower molecular weight contaminants were 
separated by this purification procedure (Figure 8 A). The yield of PH-2069 and PH-2060 protein 
was approximately 3.0 mg/1g and 2.5 mg/1g of crude extract, respectively. Two purified PH-20 
variants were dialyzed and concentrated to 4.3 mg/ml (PH-2060) and 8.3 mg/ml (PH-2069) 
respectively. Crystallization trials were performed with Hampton screening kits Ⅰ and Ⅱ. Despite 
the high purity and extensive screening neither of the two proteins could be crystallized.
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Figure 4. Ammonium sulfate fractionation of bovine crude extract (Sigma). A) 12% SDS-
polyacrylamide gel of crude extract fractions. B) Western blot analysis of fractionated crude 
extract using ram PH-20 polyclonal antibody. Both SDS-polyacrylamide gel and Western 
blot analyses were carried out under non-reducing condition. The molecular weight marker 
are indicated by M.
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Figure 5. Purification of PH-20 using anion exchange chromatography (Resource-Q 
column). A) Chromatogram of PH-20 elution profile with NaCl gradient. B) SDS-
polyacrylamide (12%, non-reducing condition) analysis of the peak fractions. C) 
Hyaluronidase acid substrate SDS-PAGE (12%, non-reducing condition) at pH 4.0. 
Lane1: flowthrough; lane 2: elution fraction. M stands for molecular weight markers 
(kDa) and SM for starting material.  
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Figure 6. Separation of immunoglobulin contaminant by Protein-G column. A) 
Chromatogram of PH-20 elution profile on Protein-G  column. B) SDS-polyacrylamide 
(12%, non-reducing condition) analysis of peak fractions, lane 1 - 2: flowthrough 
fraction; lane 3 - 4: elution fraction using 100 mM glycine pH 3.0. C) Hyaluronic acid 
substrate SDS-PAGE (12%, non-reducing condition) at pH 4.0, lane1: flowthrough; 
lane2: elution fraction. M strands for molecular weight markers (kDa) and SM for 
starting material.  
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Figure 7. Purification of PH-20 protein using cation exchange chromatography (Mono-S 
column) A) Chromatogram of PH-20 elution profile with NaCl gradient. B) SDS-
polyacrylamide (12%, non-reducing condition) analysis of proteins separated on Mono-S 
column. C)  Hyaluronic acid substrate SDS-PAGE (12%, non-reducing condition) at pH 
4.0. M stands for molecular weight markers (kDa) and SM for starting material. Fraction 
numbers (A1 to B11) are indicated at the bottom of the gel.  
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Figure 8. Purification of PH-20 using gel filtration chromatography (Hiload Superdex -75 
26/60 gelfiltration column). A) Chromatogram of PH-20 elution profile. B) SDS-
polyacrylamide analysis of the first peak shoulder shows aggregates while the main peak 
shows PH-2069 protein. C) SDS-polyacrylamide analysis of second peak shows pure 
PH-2060 protein. Protein sample were solubilized under non-reducing condition. M stands 
for molecular weight markers (kDa) and SM for starting material. Fraction numbers (C14 to 
D4) are indicated at the bottom of the gel.  
3.3.3 Purification of PH-20 from bovine testes
Purification of PH-20 protein from commercial crude extract of bovine testes has been 
discontinued due to the high cost of the extract and very low yield of pure protein. Instead, 
purification of PH-20 protein from bovine testes supplied by a local slaughterhouse was 
pursued. 
The frozen bovine testes were thawed and homogenized using buffer containing 
protease inhibitors. The homogenized sample was centrifuged and the resultant  supernatant and 
pellet were checked for hyaluronidase activity (Figure 9). Substrate gel showed maximum 
activity for the supernatant  whereas the pellet showed negligible activity. The purification 
procedure was similar to that used for the purification of Sigma crude extract (Figure 3. PH-20 
purification scheme), except for the ion exchange columns which were packed manually in 
order to handle the large volumes.  
A protein with an apparent molecular weight of about 80 kDa (PH-2080) with 
hyaluronidase activity was purified from fresh bovine testes (Figure 10 B) and identified as 
bovine PH-20 protein by MALDI mass mapping (Figure 12). The yield was approximately 
1-1.5 mg/1 kg of fresh bovine testes and could not be improved despite numerous trials. In 
contrast  to commercial crude extract, the relative amount  of PH-2066 protein obtained from 
fresh bovine testes was negligible and was not  purified to homogeneity (Figure 10 C). Purified 
PH-2080 protein was dialyzed and concentrated to 10 mg/ml and crystallization trials were 
performed with Hampton screening kits Ⅰ and Ⅱ. Crystallization was not  successful and 
precipitation was seen in most of the conditions tested which suggested protein aggregation.
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Figure 9. Homogenization of bovine testes. A) SDS-polyacrylamide (12% gel) 
analysis. B) Hyaluronic acid substrate SDS-PAGE (12% gel) at pH 4.0. Lane P and S 
stands for pellet and supernatant collected after centrifugation at 8000 rpm for 30 
minutes, respectively. Protein sample were solubilized under non-reducing condition. 
M stands for molecular weight markers (kDa).  
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Figure 10. Purification of PH-20 using gel filtration chromatography (Hiload Superdex-75 
26/60 column) A) Chromatogram of PH-20 elution profile. B) SDS-polyacrylamide analysis 
of the first peak shoulder shows aggregates while the main peak shows PH-2080 protein. 
C) SDS-polyacrylamide analysis of second peak shows PH-2066 protein with contaminant. 
Protein sample were solubilized under non-reducing condition. Molecular weights marker 
(M; kDa), starting material (SM) and fraction numbers (C7 to D12) are indicated at the 
bottom of the gel.  
3.2.4 Endoproteolytic cleavage of PH-20 protein
Purified PH-20 proteins from both commercial source (PH-2060 and PH-2069) and from 
fresh bovine testes (PH-2080) were analyzed for endoproteolytic cleavage. For this the proteins 
were reduced by DTT  and analyzed on SDS gels (Figure. 11). The PH-2060 protein (Sigma) run 
as two bands with apparent molecular weight of 35 and 30 kDa (Figure. 11 B, Lane 1). In 
contrast, PH-2069 protein from commercial source and PH-2080 protein from fresh bovine testes 
run as single band under reducing condition. This suggests that  PH-2060 protein is 
endoproteolytically cleaved and a disulfide bridge holds the two polypeptides.
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Figure 11. Purified PH-20 from two different source (Sigma crude extract and bovine 
testes). (A) non-reducing condition (B). reducing condition (12% SDS-polyacrylamide 
gel). Lane 1 and lane 2 corresponds to PH-2060 and PH-2069 proteins purified from Sigma 
crude extract. Lane 3: PH-2080 purified from bovine testes. Molecular weights marker (M) 
are indicated at the bottom of the gel. Arrows indicate reduced PH-2060 protein fragments
3.3.5 Mass spectrometry
Mascot search results of tryptic fragment  of the PH-2060 and PH-2069 proteins purified 
from commercial crude extract (Sigma) and PH-2080 from fresh bovine testes matched to the 
hyaluronidase domain of bovine PH-20 sequence (NCBI accession number: AAP55713) 
(Figure 12). This strongly suggests that  these proteins have identical N-termini. LC-MS method 
was used to determine the molecular weight  of purified PH-20 proteins. The PH-20 proteins 
purified from commercial crude extract  (Sigma) have a molecular weight  of 60334 Da and 
68780 Da, respectively. Whereas PH-20 protein purified from fresh bovine testes has a MW of 
80350 Da (Figure 13). The molecular weight estimates are based on broad peaks and therefore 
is not accurate. This may be due to posttranslational modification and may account for 
approximately 5% error. 
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Figure 12. Mascot Search Results for PH-2060 protein (commercial source). Tryptic fragments 
matched to the N-terminal region of AAP55713 sequence (deposited in the NCBI) and are 
shown in bold (top) and peptides were sorted based on increasing mass (bottom).
3.3.6 PH-20 aggregation
To test for homogeneity, sedimentation equilibrium (SE) and sedimentation velocity 
(SV) experiments were performed with PH-2080 protein purified from fresh bovine testes in the 
presence and absence of 100 mM NaCl. The result  revealed extensive protein aggregation in 
the presence of 100 mM NaCl whereas aggregation was less extensive in the absence of NaCl. 
The PH-2060 protein purified from commercial testicular extract  gave similar results (Figure 
14C). Changing the pH from 7.0 to 5.4 had no effect  on the heterogeneity of the protein 
solution (data not shown). Many additives were tested with the aim to eliminate the protein 
aggregation. Success was achieved with non detergent  sulfobetains (NDSB), which are 
zwitterionic, powerful non denaturing protein solubilizing agents used in protein extraction, 
solubilization and crystallization [25, 26]. On addition of dimethylethylammonium propane 
sulfonate (NDSB-195), at  a final concentration of 250 mM, aggregation was abolished for 
PH-2080 (Figure 14E) and PH-2060 (data not shown). Whereas in the presence of 100 mM 
NDSB-195, PH-2080 showed diminished, but not abolished heterogeneity (data not shown). 
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Figure 14. Sedimentation equilibrium (SE) experiment with purified PH-20 proteins. A) 
PH-2080 (fresh bovine testes) in the presence of NaCl. B) PH-2080 protein in the absence of 
NaCl. C) PH-2060 protein (Sigma) in the absence of NaCl. D) Non Detergent sulfobetaines 
(NDSB). The molecular structure of this compound adapted from Hampton catalog. E) 
PH-2080 protein in the presence of 250 mM NDSB-195 compound. 
 In addition to the above mentioned heterogeneous aggregates, protein aggregates with  
hyaluronidase activity eluted in the shoulder of the first  peak during gel filtration 
chromatography was analyzed (Figure 9 and 11). Under reducing condition, the aggregates 
were dissociated into many different  protein bands (Figure 15 B). By mass mapping, some of 
these dissociated proteins were identified as bovine testicular hyaluronidase (NCBI accession 
number: AAP55713), H+-exporting ATPase (NCBI accession number: A23671) and 3-
hydroxyacyl-CoA (NCBI accession number: AA19510). The latter two proteins have free 
cysteine, which suggest they are involved in disulfide bonding to PH-20 isoform. 
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Figure 15. Analysis of aggregates (indicated by red arrow) on 12% SDS-
polyacrylamide gel. A) non-reducing condition. B) reducing condition. Lane 1: sample 
is boiled; lane 2: sample is not boiled before loading into the gel. Molecular weights 
marker (M; kDa) are indicated at the bottom of the gel.  
3.4 Discussion
3.4.1 PH-20 purification
We were able to purify two PH-20 variants with hyaluronidase activity from the 
commercially available bovine testicular extract (Sigma). Though, PH-20 protein purification 
from commercial source (Sigma) has been previously reported [13, 21], we isolated them to 
highest  purity using modified protocol. Purified PH-20 variants have molecular weight of 60 
kDa (PH-2060) and 69 kDa (PH-2069) respectively, as determined by LS/MS analysis and these 
values are comparable to those reported [13]. Due to high cost and low yield of PH-20 proteins 
from commercial source, purification from bovine testes supplied by a local slaughterhouse 
was pursued. 
Although the 80 kDa band of bovine PH-20 was reported earlier [9], we were the first 
to purify the 80 kDa protein (PH-2080) with hyaluronidase activity from fresh bovine testes to 
highest  purity. Homogenization of fresh bovine testes resulted in an effective release of 
membrane bound PH-20 protein into the supernatant, which suggest PH-20 protein is freed 
either by action of released acrosomal enzymes or by mechanically affecting the stability of the 
plasma membrane. The yield of PH-2080 protein was very low which might be due to the many 
purification steps employed. Unlike the commercial source (Sigma), the PH-2065 fragment was 
presented only in negligible amount. 
The MALDI mass mapping of the protein bands correspond to PH-20 variants from 
Sigma crude extract  (PH-2060 and PH-2069) and from fresh bovine testes (PH-2080 and 
PH-2065), showed peptides matched to that of N-terminal region of bovine testicular 
hyaluronidase PH-20 protein (NCBI accession number: AAP55713). It remains to be shown 
whether the glycosylation and / or proteolytic cleavage can account for the difference in 
observed molecular weights of PH-20 proteins isolated from commercial source and fresh 
bovine testes.
 3.4.2 Endoproteolytic cleavage of PH-20
In guinea pig and macaque sperm, lower molecular weight PH-20 form is transformed 
into two lower weight  fragments under reducing condition, indicative of endoproteolytic 
cleavage of the protein into two disulfide-linked fragments [3, 7]. Our data suggested that a 
similar alteration on bovine PH-20 protein, under reducing PH-2060 transformed into lower 
molecular weight fragment of 35 kDa and 30 kDa, respectively, whereas PH-2069 and PH-2080 
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protein are intact  (Figure 17). Apart from PH-20 proteins, similarly modification occurs in 
Hyal-1 protein [27]. It was reported that bovine PH-2060 comprises of 443 amino acids, in 
comparison to the PH-20 polypeptide deduced from cloned cDNA from the same source, it 
lacks the signaling peptide (35 residues) and 56 residues from carboxyl end [13]. This strongly 
suggests that PH-2060 is probably proteolytically processed product  of the larger isozyme 
PH-2069. Structural features established by disulfide bridges, as well as glycosylation are 
essential for the hyaluronidase activity of macaque sperm PH-20 protein [12]. Similarly, the 
reduction of purified bovine PH-20 results in loss of hyaluronidase activity (data not shown).
3.4.3 PH-20 crystallization and aggregation
Based on amino acid sequence obtained from Mayar et al.,1997 [13], the calculated 
molecular weight of two PH-20 variants are 56208.9 kDa and 50240.2 kDa respectively, much 
lower than estimated molecular weight  by LS/MS analyses. The difference account  for 
approximately 18 % for PH-20 purified from Sigma crude extract and 29 % for PH-20 from 
bovine testes, which suggest the purified PH-20 proteins are heavily glycosylated. This could 
be a one major reason for unsuccessful crystallization trials of purified PH-20 proteins. 
Moreover, crystallization of PH-2080 protein showed precipitation in most of the conditions 
screened, which is indicative of protein aggregation. 
Analytical ultracentrifugation studies showed that  purified PH-20 is extensively 
aggregated both in the presence or absence of NaCl. The problem was successfully overcomed 
by the addition of dimethylethylammonium propane sulfonate (NDSB-195), at  the final 
concentration of 250 mM. It was hypothesized that the short hydrophobic group on 
sulfobetaines interacts with the hydrophobic regions of the protein and prevents their 
aggregation [25, 26]. This strongly suggests that purified PH-20 aggregates in solution by 
hydrophobic interactions, which are weakened by addition of NDSB. In addition to 
hydrophobic interaction, some PH-20 isoform, forms aggregation involving disulfide bridge in 
agreement with previous report [12].
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3.5    Conclusion
Though cloning and expression of the hyaluronidase domain of human PH-20 failed 
(M.Schmidt, unpublished data), we were successful in purifying PH-20 proteins from both 
commercial source (Sigma) and bovine testes to the highest purity except for the lower 
molecular weight PH-20 (PH-2065) from latter source. The MALDI mass mapping of PH-20 
variants from both sources matched to the N-terminal part of bovine testicular hyaluronidase 
(NCBI accession number: AAP55713). PH-2060 from the commercial source (Sigma) was 
endoproteolytically cleaved and linked by disulfide bridge, while PH-2069 and PH-2080 were 
intact. Reduction of disulfide bridges resulted in inactive enzyme (not shown), suggesting that 
structural integrity established by disulfide linkage are essential for enzymatic activity. The 
aggregation of purified PH-20 protein was successfully overcome by addition of zwitterionic 
compound, 250 mM of NDSB-195 (non detergent sulfobetaine; MW 195), which is indicative 
of hydrophobic interaction. In addition to hydrophobic interaction, some PH-20 isoforms form 
aggregation with other protein by disulfide linkage. Crystallization of PH-20 protein was not 
achieved but crystallization in the presence of NDSB still remains to be tested. In addition, 
cloning and expression of various length of hyaluronidase domain should be explored.
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